<SEC-DOCUMENT>0001445305-13-000138.txt : 20130201
<SEC-HEADER>0001445305-13-000138.hdr.sgml : 20130201
<ACCEPTANCE-DATETIME>20130201163038
ACCESSION NUMBER:		0001445305-13-000138
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20130201
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20130201
DATE AS OF CHANGE:		20130201

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		13567083

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>sohoindonesiaagreement8k.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using WebFilings 1 -->
		<!-- Copyright 2008-2013 WebFilings LLC. All Rights Reserved -->
		<title>Soho Indonesia agreement 8K</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s88A3B09D19BEB0A71310966BC31914E7"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;">FORM 8-K</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">CURRENT REPORT</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="51%"></td><td width="5%"></td><td width="44%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of Report (Date of Earliest Event Reported):</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 1, 2013 (January 29, 2013)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;">Cumberland Pharmaceuticals Inc.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">__________________________________________</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td width="0%"></td><td width="33%"></td><td width="18%"></td><td width="5%"></td><td width="11%"></td><td width="33%"></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Tennessee</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">001-33637</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">62-1765329</font></div></td></tr><tr><td><font>&#160;</font></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction of incorporation)</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission File Number)</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(I.R.S. Employer Identification No.)</font></div></td></tr><tr><td><font>&#160;</font></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2525 West End Avenue, Suite 950, Nashville, Tennessee</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37203</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registrant's telephone number, including area code:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(615) 255-0068</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">____________________________________________</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Former name or former address, if changed since last report</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s88A3B09D19BEB0A71310966BC31914E7"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.01 Other Events.</font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 29, 2013 Cumberland Pharmaceuticals Inc. issued a press release announcing  it has entered into an exclusive agreement with Indonesia's PT. SOHO Industri Pharmasi (a SOHO Group company) for the registration and commercialization of Caldolor&#174; (ibuprofen) Injection, which is used to treat pain and fever in the hospital setting. A copy of the press release is attached as Exhibit 99.1.</font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s88A3B09D19BEB0A71310966BC31914E7"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="68%"></td><td width="32%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cumberland Pharmaceuticals Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">February 1, 2013</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">By: Rick S. Greene</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Name: Rick S. Greene</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Title: Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:15px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:384px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:384px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:384px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><hr></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit&#160;Index </font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.5625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="20%"></td><td width="13%"></td><td width="67%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press release dated January 29, 2013</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s88A3B09D19BEB0A71310966BC31914E7"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;"><img src="cumberlandpicture.jpg" style="height:155px;width:682px;"></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FOR IMMEDIATE DISTRIBUTION</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CUMBERLAND PHARMACEUTICALS AND PT. SOHO INDUSTRI PHARMASI</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;ENTER INTO exclusive licensing AGREEMENT </font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">for CALDOLOR IN INDONESIA</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">-Indonesia has the World's Fourth Largest Population</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Nashville, Tenn., (January 29, 2013) - Cumberland Pharmaceuticals Inc. </font><font style="font-family:inherit;font-size:12pt;">(NASDAQ:CPIX) today announced it has entered into an exclusive agreement with Indonesia's </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PT. SOHO Industri Pharmasi (a SOHO Group company)</font><font style="font-family:inherit;font-size:12pt;color:#333333;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">for the registration and commercialization of Caldolor</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">ibuprofen)</font><font style="font-family:inherit;font-size:12pt;">&#32;Injection, which is used to treat pain and fever in the hospital setting. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Under the terms of the agreement, SOHO receives an exclusive license to Caldolor for the Indonesian market. SOHO will be responsible for seeking regulatory approval, ongoing regulatory reporting, product marketing, distribution and sales in the territory following approval. Cumberland maintains responsibility for the intellectual property, product formulation, manufacturing and other supported activities. In exchange for the license to the product, Cumberland will receive upfront and milestone licensing payments, as well as transfer prices on future sales of the drug. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;We are delighted to partner with SOHO to introduce our product in Indonesia and to help support the quality of care available to hospitalized patients in that country,&#8221;said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. &#8220;Expanding into new international markets is a key component of our growth strategy, and this partnership represents an important milestone in achieving that strategy and establishing a strong presence in Asia.&#8221; </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">While Cumberland focuses its proprietary commercial efforts on the United States, the Company has significantly expanded its international network of partners in recent years. In addition to its arrangement with SOHO, Cumberland has licensed rights for Caldolor to partners in China, South Korea, Malaysia, Dubai, Canada, Australia and New Zealand.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;There is a significant and growing body of research that supports the safety and efficacy of Caldolor,&#8221; said Marcus Pitt, President, Director and CEO of SOHO Group (a holding company of PT. SOHO Industri Pharmasi). &#8220;Due to Caldolor's attributes and strong performance in clinical trials in the United States, we are excited to share this innovative product with physicians and patients throughout Indonesia.&#8221;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Following regulatory approval, SOHO will use its existing sales force to promote Caldolor throughout Indonesia. The product features analgesic, antipyretic and anti-inflammatory properties and is designed for the treatment of pain and fever, primarily in hospitalized patients who are unable to receive oral </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s88A3B09D19BEB0A71310966BC31914E7"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">therapies. In clinical trials, Caldolor has demonstrated significant reductions in post-operative pain when compared with opioids alone while significantly reducing opioid requirements. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">SOURCE: Cumberland Pharmaceuticals Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About Caldolor</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup>&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Caldolor is indicated for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, and for the reduction of fever in adults. It is the first FDA approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticaria, or allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. Caldolor should be used with caution in patients with prior history of ulcer disease or GI bleeding, in patients with fluid retention or heart failure, in the elderly, those with renal impairment, heart failure, liver impairment, and those taking diuretics or ACE inhibitors. Blood pressure should be monitored during treatment with Caldolor. For full prescribing information, including boxed warning, visit </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">www.caldolor.com</font><font style="font-family:inherit;font-size:12pt;">. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">About SOHO Group</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">SOHO Group is one of Indonesia's leading pharmaceutical and healthcare corporations in manufacturing, distributing, and providing quality health products and services.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The corporation consists of 3 synergy business under SOHO Group: SOHO Group PHARMA (</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Prescription market: Branded Generics, Natural &amp; TCM Product, Low Price Medicine, Medical Device, and Alliance Business</font><font style="font-family:inherit;font-size:12pt;">), SOHO Group COSTUMER HEALTH (</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">OTC Product, Consumer Health Product, Hezzel Farm Product and Unihealth MLM Product</font><font style="font-family:inherit;font-size:12pt;">), SOHO Group DISTRIBUTION (</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Distribution arm of SOHO Group &amp; Other Principal, Raw Material Trading Business, and Retail Business "Apotek Harmony&#8221;)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">They focus on manufacturing - including under-licensed - herbal products (</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">immunomodulator, antioxidant, anti diarrhea, anti laxantia)</font><font style="font-family:inherit;font-size:12pt;">&#32;and synthetic products (</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">antibiotic, cephalosporin, injection preparation, antiemetic, analgesic, musculoskeletal, vitamin, obgyn, gastro, neuro, and rheumatology products</font><font style="font-family:inherit;font-size:12pt;">). SOHO distributes pharmaceutical and healthcare products for their companies, and other pharmaceutical and consumer goods manufacturers. For more information, please visit </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">www.sohogroup.com</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About&#160;Cumberland Pharmaceuticals</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland Pharmaceuticals Inc.&#160;is a&#160;Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology.&#160;Cumberland's product portfolio includes Acetadote</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">acetylcysteine</font><font style="font-family:inherit;font-size:12pt;">) Injection for the treatment of acetaminophen poisoning; Caldolor</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174; </sup></font><font style="font-family:inherit;font-size:12pt;">(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">ibuprofen</font><font style="font-family:inherit;font-size:12pt;">) Injection, the first injectable treatment for pain and fever available in&#160;the United States; and Kristalose</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">lactulose</font><font style="font-family:inherit;font-size:12pt;">) for Oral Solution, a prescription laxative.&#160;Cumberland&#160;is dedicated to providing innovative products which improve quality of care for patients. For more information, please visit the company website at&#160;</font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">www.cumberlandpharma.com</font><font style="font-family:inherit;font-size:12pt;">. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Important Note Regarding Forward-Looking Statements</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This press release contains forward-looking statements that reflect&#160;Cumberland's current views with respect to future events, based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of operations are subject to influences outside of the Company's control. Risk factors that could materially affect results of operations include, among other things, market conditions, intense competition from existing and new products, an inability </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s88A3B09D19BEB0A71310966BC31914E7"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">of manufacturers to produce Acetadote on a timely basis or a failure of manufacturers to comply with stringent regulations applicable to drug manufacturers, maintaining and building an effective sales and marketing infrastructure, government regulation, the possibility that patent rights may provide only limited protection from competition, and other factors related to the Company including those under the headings "Risk factors" and "Management's discussion and analysis of financial condition and results of operations" in&#160;Cumberland's Form 10-K filed with the&#160;SEC&#160;on&#160;March 7, 2012. There can be no assurance that the results or developments anticipated by&#160;Cumberland&#160;will be realized or, if realized, that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof.&#160;Cumberland&#160;undertakes no obligation to release publicly any revisions to these statements to reflect events or circumstances after the date hereof.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">#</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">#</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">#</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Contacts:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Investors:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Elizabeth Davis</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland Pharmaceuticals</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">615-255-0068</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">investors@cumberlandpharma.com</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Media:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Rebecca Kirkham</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Lovell Communications</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">615-297-7766</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">rebecca@lovell.com</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>cumberlandpicture.jpg
<TEXT>
begin 644 cumberlandpicture.jpg
M_]C_X``02D9)1@`!`0$`W`#<``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`#3`Z`#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]]****`"B
MBB@`HHHH`****`"BBB@`HHI&<*"3VH`6BOG'Q#^TP-7_`."GGAOX5:=J4_E:
M5X#O_$&KVL4Q$9DFO+6&W\Q0<%E6.8C/($G'WN?HZM:M%TU'FZJY$*D9WY>@
M4445D6%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44$X'-->3:A
M.1P,B@!U%>5?$#]LOX?_``WN9[6[\06VHZA;$K)8Z3$^H7,9]&2$,4_X%C\*
M\*^*7_!6^/PY%(OA[P#J%XPR%FU:_CLD^NR/S6_`[3770P->LTH1_3\R934=
M6?8[7"+U8#!QR:\`_;M_X*)_#[]A3X>7FH^)-5@NM=>%CIN@VLJM?7\FT[1L
MY*1YZR,`H]SQ7YZ_M'_\%:?C1XVM+BUT[5M*\'6DFY=NB6>+@J>S33-(V?=`
MAK\ZOC=K-[XGU6]U'4[V\U+4+QB\]U=S-//,WJSL2S'ZFOH\MX4E4FI8F5H]
MEU/.QF.]G%N!]M_\$'?V@_$'[5?_``6&^(_CWQ3.)M7\1>&+R>15SY5NGVFT
M5(4'9$0*H]A[U^XU?@#_`,&PXQ_P47\2_P#8G77_`*56M?O]7/Q;3C#'\D59
M*,4C#(9.6&O+75_F%%%%?,GM!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!110
M3@?2@`J#4M1BTJS>XGDCBAB!9WD<*J*!DDD\``5Y]^T3^TSX7_9S\)+J>OW3
M_:)RR6&GV^'N]1E`SLB3(SC/+$A5!R2!7QEXX^./B7]IS5A)XG>.VT$2;K;P
M];RL]FG(PT[$#[2_?Y@$4]%R-Q[,+@IUES[1[_Y$2J):'T_XH_;+A\52R6'P
M]TQ/$;ABC:O<RFWTJ(@\E&`+W&/2,;#T\Q:Y?Q-X%U'QMI#7'B_Q%J/B$R#<
MUC'_`*%I:^PMT.7'M,\E<]\.3^[C`X```'85Z3K/_(`_X#_2JJ)4Y)4_^#_7
MH"5]6?/OQ!TFUT&Q%I96\%I:PC;'%"@1$`[`#@"OFGXJ]9/K7T_\5_O2?C7S
M!\5>LGUKZ/+=;7,*VB/FOXH?ZQZ^>/BE_JY?Q_E7T/\`%#_6/7SQ\4O]7+^/
M\J^SP?0\3&_`SZK_`.#8C_E(OXD_[$ZZ_P#2JUK]_J_`'_@V(_Y2+^)/^Q.N
MO_2JUK]_J^$XQ_Y&+_PHZ>'_`/=?F_S"BBBOECW`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@!&8(N2<`5X_\`MC_M?:#^R1\-FU?4"+[5[_=;Z1I2/MEU&<#.
M,_PQJ,%W/"CU)4'T#XJ_$K1OA#\.M:\3:_>Q6&D:%:O>7<SG[J*,X`ZECP`H
MY)(`Y-?B#\=_VG-9_:X^-]_XPUAI(893]GTNP+Y33+-6^2(=MQ^\[?Q,3V"@
M>SE&5O%3<Y?!'?S\CFKUN33J>C:E\4=?^-_Q"NO%/BB_.HZS??)N"E(;6($E
M8(4R=D8].K')8DG->M_#O[D7U%>"_#P;O+QSTKVSP1XFL=/O(;1YUEOGP4LX
M$:>ZE_W(8P9&_!37TN,IQ@DDK6_`RIZ[GT;\.?N1_05Z3K/_`"`/^`_TKS/X
M:^'/&NJ0(^F^`O$3Q\8FU+RM,B/_``&9A,/^_1KTE?A!\2O$EH(KBY\'>'HN
M,JL5SJLF/KFW4'\Z^1KI<]^9?>=46TCP?XL.`S\^M?,/Q6X,F?7-?H)=?L%C
MQ#('UGQSXGG9N7CL;.SMH3]`\,CC_OL_6GP?\$P?A1<X.IV7B+5Y!U:XURYB
M#_5871?TKT\+F5"C;F;?HO\`.QG*$IZ(_&7XH#]Y)[5\[_%-L)+P>_:OZ,+7
M_@F'\"+:0,WP[TN[8=[NYN;K_P!&2-5I?^":?P"`.[X1^!9<]?-TJ*3_`-"!
MKV*7%F&I[0;^XX:^7SG&US\</^#8MQ'_`,%%_$N3C_BCKKCO_P`?5K7[_;AC
M-?GI_P`%)_V:?`'[,.@^$M3^'7A#0/`^HZA<W,%S<Z)9I8S3QB-#L9XP"5S@
MX)QQ7RA%\:/&.BR!K3Q9XEMBG(\O5)UQ^35\WG>9QQV)]O"-E9+7R-LMP<L-
M1]G+75_B?MV2!U-&><5^,FC?MT?%WP<X-CX^U\XYVW,JW2_B)0V?QKT;P)_P
M66^*GA"2--8M?#GB6$<.9K4VTS#V:(A1^*'Z5Y!Z!^JM%?$_PI_X+<^`_$K1
M6_BS1-8\+SM@//$/MMLOOE0'Q_P`U]4_"?X]>#?CCI1O/"?B71]>B49=;6X5
MI8O]^/[Z'V8"@#KZ*`<T4`%%%%`!1110`444-P#GI0`45\T?\%#/^"J/PM_X
M)O>'=/G\;:C=7FM:PK/IVAZ9&L]]=JIP9""RJD8/&]V`)!`R0<?"-W_P=U^$
M([IQ!\&?$LL&?D:37((W(]P(F`_,UZF$R3'8FG[6C3;7?1?F>?7S3"T)>SJU
M$GV/V%HK\=Q_P=W^%/\`HBOB#_PH(?\`XS1_Q%W^%/\`HBGB#_PH(?\`XS77
M_JOFG_/I_>O\SG_M[`?\_5^/^1^Q%&>:_'?_`(B[O"G_`$13Q#_X4$/_`,9K
ML/@S_P`'7GPE\;^*;:P\7>!_%G@JTN)%0WZRQ:E!!DXW.$VN`/55:HGPUF<8
M\SI/[T_U*AGF!DTO:K\3]6**R?!'C;2?B-X3TW7=#U"TU72-8M8[RRO+6420
MW4,BADD1AP5((((]:UJ\-IIM,]5.ZT#/-&:^9/\`@J-_P4@L?^"9?P6TGQIJ
M/A>]\66VJZNFE"UMKM;9D+122;]S*PQ^[QC'>OGS_@GK_P`'#&A_\%!/VI=%
M^&.G?#35_#5SJ]M=7"WUQJT=RD8@A:4@H(E)R%(Z\5Z%+*L54P[Q4(>XMWIT
MW..IF&'IUE0E/WGT]=C]'J***\\[0HSBBN(_:-^,2?L^_`WQCXXELI=2@\(:
M)=ZS):QN$>X6")Y"@8@@$[<9(-.,7)J,5JQ-V5V=OFBOQYM?^#N3PMJ%[#`G
MP7\0)YKA,G7X3C)`_P">-?L)$Q:-21@D#(]*[,;EN*P=OK,>6^QR87'T,3?V
M$KVW'445\O?\%3?^"EUC_P`$Q/A)H/B[4?"EYXLM];U8:6+>VO%M6B8Q22;B
MS*P(^3&,=ZPP^'J5ZBI4E=O9&]:K"E!U*CLD?4-%?GE_P3J_X.%O`G[?GQW_
M`.%?S>%K[P#K%[;--I+7VHQW,>J2*<O`K!%VN$^8`YW8('(P?T,5PW0@_C6F
M,P=;"U/98B/*R,+BJ6(A[2E*Z%HHHKE.@***\C_;<_;$\+_L-?LZZ[\1?%$P
M:QT>,+!:1N!-J-RW$5O'G^)C^0!/05=.G*I-4X*[>Q,YQA%SD[)'KF:*_(7P
MC_P=D^%_%WBS2M(C^#6OV\FIWD-H)3KT3",R.$W$>3R!G.,U^N]N[20J6&&(
MYKKQN6XK!M+$PY;['+@\=0Q,7*C+FL/HS01D5\I?\%5?^"H>G_\`!+KX>^%O
M$.H^$KWQ=%XHU&33DAM[U;4P,D1DW%F1L@@8Q7/A\/4KU%2I*\GL;UZT*,'4
MJ.R6Y]6T5^.X_P"#NWPJ3C_A2GB'_P`*"'_XS1_Q%W^%/^B*>(/_``H(?_C-
M>S_JQFG_`#Z?WK_,\S^WL!_S]7X_Y'[$45^._P#Q%W^%/^B*>(/_``H(?_C-
M'_$7?X4'_-%/$'_A00__`!FC_5C,_P#GT_O7^8?V[@?^?J_'_(_8BC/.*_'_
M`$G_`(.Z/!-QJ4*7WP<\46MH6Q)+!K,$[H/4*8U!^FX5^B7[#7[??P[_`."@
M?PN/BKX?ZL;N&V<0ZA87,?DWNES$9$<T>3C(SA@2K8.":XL9DV-PL?:8BFU'
MONOO1TX7,\+B)<E*HF^Q[=10#D9'(--E)6)B.H'%>:M3O'9HK\DOBA_P=:>&
M/A?\2_$?AJ?X/:[>R^'M4N=,>=-=B03&&5HRP7R3C.W.,]ZQ!_P=W>%#_P`T
M4\0?^%!#_P#&:]V/#.9R2E&E=/S7^9Y#SW`IM.HE;O<_8BBOQW_XB[_"@./^
M%*>(/_"@A_\`C-'_`!%W^%/^B*>(/_"@A_\`C-5_JQFG_/I_>O\`,7]O8#_G
MZOQ_R/V(HK\=S_P=W^%!_P`T4\0?^%!#_P#&:[K]F+_@YZ\._M.?M$^"OA[9
M_";6](N/&6KV^DQWDNM13);-,X0.4$0)`STS45.&\RA%SE2LEYK_`#*AG>"E
M)1C55WZGZG4$X%(IR!GK7'?M%?%N/X`_`#QOX[ELI-1A\%Z#>Z[):(X1KE;6
M!YC&&((4L$(R0<9KQ8Q<FHQW9ZDI**;?0[*BOQT7_@[L\*+_`,T5\0?AX@A_
M^,T__B+N\*?]$4\0?^%!#_\`&:]S_5C-/^?7XK_,\IY[@/\`GZOQ/V(HK\=_
M^(N_PI_T13Q!_P"%!#_\9H_XB[_"F?\`DBGB#_PH(?\`XS3_`-6,T_Y]/[U_
MF+^WL#_S]7X_Y'[$9YHK\>K/_@[L\'2WT2W/P:\30VY8"1XM;@D=%[D`QJ&/
ML2/K7Z`_L#_\%*/AO_P48^'MWKG@#4+D7&DR)%JFE7\0AOM-=P2N]`Q!5L-M
M=25.UAG((KDQF2X["Q]I7IM1[[K\#IPV9X6O+DI339]"4=**CN79$&WJ3BO+
M.\DS17Y1_'[_`(.E?#?P'^-_C#P//\(M=U"Y\(ZS=Z/)=IKD4:W#03-$7"F(
MX!VYQDU]_?L'_M7V_P"W#^REX3^*5IHT_A^V\5I<21V$TXG>W$5S+;G+@*#D
MQ$\#O7?BLKQ>'I1KUX6C+;Y['%0S'#UJCHTY7DMSUZBBBN`[0HHHH`****`"
MBBH-1OH].L9;B61(H85WR.[`*BCJ23P`!WH`GSBBOR0^)7_!V1X%\&>/];TC
M2/A=K?B33M,O9K6UU2/68[=-01&*B54,1*JV,C)Z$5]V_P#!-_\`X*#^&?\`
M@HY^SQ%X[T&W;2)XKR6PU#29[A99].F0@@,0!D,A5U.!D-Z@UZ6+R?&X>FJU
M:FU%G!ALRPU>;ITYIM=#Z"HHHKS3O"@G%%)(2J$@$D#C%#V`6BOS6_;R_P"#
MB_0OV%/VIO$GPQU#X8:QXBN?#PMRU_!J\=NDPE@2480QL1C?CKVKZA_X)V?\
M%)/`/_!1OX0KXE\*7:V6J6F(]7T*YE4WFDR^C`?>0_PR`88>AR!Z%;*L72HK
M$U(6@]GZG#1S'#U:KH0G>2Z'T110"&&0<BBO/.X***\^_:K^/$?[,/[.OC'X
M@S:=)J\'A#2I]4DLXY1$]PL2[BH8@A2?4BJA"4Y*$5=O0F4E&+E+9'H.:*_*
M?]GC_@Z.\-_M!?'?P9X$MOA'KFFW/C#6K31H[N37(I$MVGF6(.5$0)`W9QGM
M7ZJP,7A4GKWKKQN7XC"24<1'E;U6WZ'-A,;1Q,7.A+F2'T$XHKF_B_X_'PK^
M&'B'Q*UNUW'X>TRYU-X%;:TRP1-(5![$A<9]ZXTFVDCJ;25V=)17XZI_P=V^
M%`@)^"GB#T/_`!4$/_QFG?\`$7=X4_Z(IX@_\*"'_P",U[O^K&:=:7XK_,\E
MY[@;_P`5?B?L117X[_\`$7?X4(_Y(KX@_P#"@A_^,T0_\'=GA)YP)/@QXD2/
MN5UZ!C^1A'\Z/]6,T_Y]/[U_F"SW`?\`/U?C_D?L117YG?"+_@Z:_9\\>ZA#
M;>(M,\;^"3*0IN+W3X[NWC/N;=W?'OL_"OO;X"_M*>!OVG?!4/B/P%XKT3Q7
MHLWRFYT^Y641/_<=?O1N.ZN`1Z5YV*RW%X7_`'BFXKO;3[]CMP^.P^(_@S3?
M:^IW=%(&##(((J&_U"'3K:26:6.&.)"[.[!54`9))/0<5Q'5>Q.3BC-?(6H?
M\%A/!GB/Q%?V/PW\$_%/XRVVE3-!>:IX,\-R7FEQ2*3E%NG9(Y&_ZYEL]LUZ
M/^RK_P`%#/AY^UCXBU+P]I-UJWA[QIH<?F:GX5\2:=)I.M6*\?.UO+@LG(^=
M"RC(R1FNJ>!Q$(>TG!I+?^NASQQ5*4N521[M12!@PR""#2URG0%%%0:E,MM:
M-([!$C&YF/\`"!UI!?N?F+_P7X_:KD_MOP_\']+NML3(FN:\%;&X9(M86_X$
MK2D>T9KY1_91_9L\<?M):X;+P=H,^J);/LN;V1O)L;,]<2S$8#8.=B[GQ_#7
MLO[+O[&>I?\`!5?]L7X@?%GQ1->6'PXDU^9(9D)6;65A8116\3?P(D,<8=QR
M#E1\V67];?AM\.-%^$O@VS\/^'=+L=&T?3D\NVM+2(1Q1+]!W)Y)/))YS7VE
M;,J>78>.$H*\UK+U>_J>;2I2K3=66W0^3OV>O^"1&A^&;..Z\>^(+_Q%>@#=
M8:<[6-@GLS*?.D^N]%(_@KZF^'OP7\+_``GTT6?AK0M)T.WP`5L[5(B^.[$#
M+'W))KJ**^5KXRM6=ZDKG?&G%;"*-J@>E+117,6%%%%`!1110!\5_P#!9S_D
M1?`W_7_=?^BDK\\[_J:_0S_@LY_R(O@;_K_NO_125^>=_P!30!E7G4_2LFZ^
M^?K6M>=3]*R;K[Y^M`&5=_Q?Y[5!HOBO4_!>M1:CH^H7NEW]NVZ.XM9FBD0^
MS*014UW_`!?Y[5DWGWC0!]S?LG?\%B_&W@HV^G^.[=?&&E*`INU`BU&(=,[A
M\LGT8`G^]7Z+?`O]I#PC^T5X?%_X6U6&\"*#/;-^[N;0G^&2,\K]>A[$U^$?
M@SJGUKVGX0^+=4\">(+75=&O[K3-1M3F*XMW*.N>H]U/=3D'N*`/VNHKYL_9
M*_;JM_BFUKH/BT0:;XB<".WNDPEKJ1]!_P`\Y#_=)(/\)_A'TDC;U!Z4`+11
M10`4V;F%^<<'FG4C_</TII`?S!_\'"?Q*O/B)_P56^(<%S</-;^&%LM'LUW9
M6&-+6.1E`[?/*Y/N37J/_!,[_@WS3_@H=^RMIOQ+;XIMX4.H7MU9_8!X?^V!
M/)D*9\SSTSG&?NUX%_P6]_Y2L?&G_L-K_P"D\-?M3_P;._\`**GPU_V&]4_]
M*&K]4S+&UL#DU&>%ERMJ/1/=7Z^A^?9?AJ>*S6M#$+F2YG^-CY5_XA#8C_S7
MEO\`PD?_`+KH_P"(0V'_`*+RW_A)?_==?M517Q:XJS3_`)^_A'_(^G_U>R__
M`)]K\?\`,_%4_P#!H="!C_A?+G_N4O\`[KK\Q/\`@HA^QX/V#OVL?$7PQ&OG
MQ-_8,=N_]H&T^R^=YL"2X\O>^,;\?>/2OZY3R#7YK_M^_P#!NAHW[>7[4OB#
MXG7OQ3U3PW<:\ENC6$.BQW*0^5"D7#F52<[,].]>SD?%M95W_:%3W+=EOTV5
MSR\UX<I.BOJ<$I7[O;YLW/\`@V4^)U[\0?\`@F7IUA?3O._A37+[28"Y)*P9
MCG1?HIG8>P`%?H97S9_P2_\`^"=EG_P31^`M]X$L?%%UXLAO=6EU7[9/9K:L
MIDCB39L#-P/+ZY[U])U\GF=:E6Q=2K1^%MM'T>7TZD,/"%7XDE<_+C_@Z_\`
M^3#O"'_8Y0?^DMQ7YR?\&V'_`"EE\%?]@O5O_2&:OT;_`.#K_P#Y,.\(?]CE
M!_Z2W%?G)_P;8?\`*67P5_V"]6_](9J^^RG_`))VKZ3/C\T_Y'-'_MW\S^F*
MBBBOS,^["O$O^"DG_)@'QN_[$76/_2*:O;:\2_X*2?\`)@'QN_[$76/_`$BF
MKHPG\>'JOS,J_P##EZ'\D>@?\ARS_P"N\?\`Z$*_M(3[@^E?Q;Z!_P`ARS_Z
M[Q_^A"O[2$^X/I7W7'OQ4?\`M[_VT^-X.^"I_P!N_J+7Y4_\'9G/[%O@#_L<
M5_\`2.XK]5J_*G_@[,X_8M\`?]CBO_I'<5\QPY_R,Z/^+]&?19W_`+C4]&?@
MSX+\3:Q\/?$>F^(]%N;O3=1T>\2XL[Z`E&MKA"&1E;^\,9_"OZC_`/@D+_P4
M6TW_`(*-_LO6?B)WMK?QEH833_$UA&<>1=!<B55[12@%E]#N7JIK\1_^"57[
M!,W_``4%_8R_:4\-Z6J-XN\,S>'=<\.[B%$ERJ:JKP$]A+'\OIN"'M7DW_!-
M3]N;Q)_P3)_:ZM/$;P7JZ7YQT?Q5HT@*//;;\2*5.`)HF&Y2<$%2O`8U^@9[
M@J69PJ4J=O:TMN[32=O1_F?&Y/BI8%TZD[NG4_!IVO\`UT/ZOJ*YWX4_$_1/
MC)\/=%\3^'+Z'4]"UVSCO;&[A8%)XG4,K#\#R.QR#R*Z"1Q$A8]!7Y+*,HOE
MDM3]&335T$F`IST(YK^;?_@X'_X*5/\`MK?M+KX&\*WSW/P^^'EP]I;-`VZ/
M5[_[DUQQ]Y5(\N,^@8C[]?IC_P`'"W_!3$?L=_LWCP/X7O3!\1/B/;2VL31O
M^\TJP^Y-<\<JS9,<9]=Y_@K\CO\`@D/^P/J7[4_C;Q?X\O;5QX)^%6B7FKW5
MPZ?)=WR6LCVMNN>I#J)&]%3G[PK[GA?`TZ%.69XG1+2/KM=>?1'RF?8N=:K'
M`4-WK+T_K<^7/@H#_P`+B\)GG_D,V?\`Z/2O[*XO]4OTK^-7X*C'QC\)^G]L
MV?\`Z/2O[*HO]4OTK;CQ>_1])?H8\(_PZO\`B7Y#J_(__@[C_P"3:?A+_P!C
M1<?^DC5^N%?D?_P=Q_\`)M'PE_[&BX_])&KYSAG_`)&='U?Y,]O/O]PJ>GZH
M_*;_`()=_L*0?\%%/VI[?X;S^))O"T<VEW6H_;H[,73#R0OR["Z]=W7/:OTH
M'_!HIIA_YKA?#V/AI/\`Y)KY7_X-C6V?\%1K`XS_`,4SJ7\HJ_I#2Y`0#*\#
MU/\`A7T_%>=XW"8WV6'G9<J>R>_J>!D&5X3$83VE>%W=_AZ'XR?\0B>F?]%Q
MO?\`PFD_^2:7_B$5TQ>OQOOC_P!RTG_R37[-_:AZK^9_PI#=J.Z_G7S/^M>:
M=:OX1_R/:_U?R[_GW^+_`,S^8'_@K1_P1SUS_@EV_A;4'\5VOC+PWXK>:W@N
MUL393VT\2JQC>/>X(96RK!OX6!`XS[;_`,&J7Q"U'0/V]O$_A^&:3^S-?\(W
M$MS"3\AEAN+=HY,>JAY!]'-?27_!W%XGL7^#/P>TK[3$-1?6[ZZ6WW?O#$L"
M*7QZ!F4?4U\J_P#!K5IMQ=?\%(=3GBAD>&S\&WSS.!Q&#/:J,_4L!^-?;+&5
M<7P_.KBM96>O?6R/FUAJ>'SJ%.AI&ZT^1_1;&,(.U*_W#]*2'F/\3_.E?[A^
ME?E4%;0^_9_'9^UG_P`G4_$S_L:]4_\`2R6OT?\`V//^#96/]J_]F+P1\1C\
M8VT(>,=)AU,6'_"-BX^S;QG9O^TKNQZX%?G!^UG_`,G4_$S_`+&O5/\`TLEK
M^GG_`(([2"+_`()A_!#//_%)VG3Z&OUCB/,L3@\%1GAI6;LMD^E^I^=Y!@:&
M)Q52->/,EK^)^>'_`!"'1$_\EY;G_J4O_NNC_B$-A_Z+RW_A)?\`W77[2BZ7
M%#7:J,X-?%/BG-5_R]_"/^1]7_J[E_\`S[7X_P"9^+1_X-#8?^B\M_X27_W7
M7??LK?\`!L,G[+O[2W@7XAI\9#K9\&:S;:O]A/AK[.+KR9`_E^9]I;;G&,X-
M?K6C[UR.E+6=3B;,JD'"=31Z/1?Y%0R'`0DI1IJZ]?\`,1>G?I7C/_!1[_E'
MG\=_^R>Z_P#^FZXKV>O&/^"CW_*//X[_`/9/=?\`_3=<5X^#5JT%YK\STL3_
M``9^C_(_D8TRT^WZA;P;MGGR+'NQG;EL9K]JK;_@T=TRZMTD'QNOUWJ&P?#2
M<9'_`%\5^+7A_P#Y#MC_`-?"?^ABO[/]'_X\(_\`<7_T$5^G<79IBL&J7U:7
M+>]]$]FNZ/@N&<NP^*C4]O&]K6WZGXT_\0B>F_\`1<+[_P`)I/\`Y)I/^(13
M3`1GXWW_`"?^A:3_`.2*_:&BOB_]:<T_Y^_A'_(^I7#V7_\`/M?C_F?S!_\`
M!6?_`((Q:[_P2^L_#FM#Q9;>-/"OB2Y>RCO%L393V=PJ;Q')'O<$,H8A@W\#
M9`XSZ/\`\&NGC?4/#W_!2:?2+>9EL/$'A>]CNXLG:_E-%+&V/4%2![.:^X?^
M#LCG]B;P+T./&4?_`*1W%?!'_!LC_P`I2M'_`.Q=U/\`]%K7VE'&5<;D%6KB
M7=VDNVQ\S/"4\+G5.G0T3:_$_I*!YQ22]%_WA3J;+T7_`'A7Y5>ZN??/8_D3
M_P""BW_)_OQJ_P"QXUC_`-+9:_HH_P""`'_*(?X.?]>NH_\`ITO*_G7_`."B
MW_)_OQJ_['C6/_2V6OZ*/^"`'_*(?X.?]>NH_P#ITO*_2^+?^170]8_^DGP_
M#W_(QK?]O?\`I2/L:BBBOS4^Z"BBB@`HHHH`*_.W_@XP_;_/[*/['5SX+T2\
M^S^,?BBLFE6QC?$EK8``7<WJ-RMY0/K(2/NU^@GB36;7P[HMSJ%]/%:V=E&T
M\\TK;4AC12S,Q[``$GV%?RI?\%3/VS]0_P""B/[<FO\`BBQ6YN-'-RNB^&;-
M,L5M(VV1%5_O2N6D(QG=+CM7TW"V5_6\7[2:]V&K_0\+B#'?5\,XP?OST7ZG
M'?LY_L+>.?VG/@C\4?'OANS,NB_"K3H]1U'*$M=;GRT<78LD*R2L.<*@_O"O
MH_\`X-\?V^Q^QS^V5;>'=;O?L_@?XF-#I.H>8_[JSNPQ%K<Y/``9F1C_`'9,
MG[HK]M?^"4O[!EC^Q!^PAX?\#WUG;3ZWJMN^I>)@R!A=7EP@\V-N/F5$"1#U
M$>>]?SS_`/!5[]B:Y_8&_;7\3^#X(I4\.W4O]K>'9N</8S,6C4'UC8-&?=,]
MZ^OPN;4LVG7P-3X6O=[Z:7^_4^:K9?4RZ-+&0UE]KY_\#0_K`HKXL_X(7?M\
MI^W1^Q7I4^JWJW'CCP6L>A^(`S9EN'C3$-T<\GS8QN)_OA_2OM.OS+%8:>'K
M2HU%JG8^\H5X5J<:D'=-7"BBBN<U9_,%_P`'#!/_``]E^)8[%-._](8*^>?V
M3?VKO'7[$/QNTKQSX(U";3-6LB/,@DW&VU"W;!:&9.-\;K^7!!!`(^AO^#A?
M_E+-\2\]/+T[_P!(8*]_\'_\$AY_V^?^"+_PJ^)?@*UB'Q4\+VVIV;VO`_X2
M.SAU.[58<D@"9`#L)X(^4]B/V.GC,/1RW#QQ2O":C'RU74_,ZF'JU<?6=!VE
M%MJW6S/UI_X)G_\`!2OP9_P4@^"=OK_AZ6.P\0:>JQ:[H<DH-QIDV#SCJT3$
M$HX&",@X(('TK7\@?[,_[2WQ!_8`_:(MO%/A>>ZT+Q/X>N6M[^PNHV5;A5($
MMK<Q$@E3C#*>01D$$`U_3#_P3(_X*<>"/^"D?P936M`8:9XETW;%KF@S2AI]
M.E/1@?XX6YVN!S@@X((KX3B'AZ6"E[>CK2?X>OEV9]?DV<QQ4?9U-)K?S/IN
MOGC_`(*S_P#*-;XV_P#8H7__`**-?0]?/'_!6?\`Y1K?&W_L4+__`-%&O!P/
M^\T_\2_-'K8O^!/T/YGO^":__*0KX(?]CSH__I;%7]<MO_J5^E?R-?\`!-?_
M`)2%?!#_`+'G1_\`TMBK^N6W_P!2OTK[+CS_`'BC_A_4^7X._P!WGZ_H/KSC
M]K__`)-6^)?_`&*>J_\`I))7H]><?M?_`/)JWQ+_`.Q3U7_TDDKXG#_Q(^J/
MK:GPL_CWM(?M%S''NV^8P7.,XR?2OV9\/?\`!I+'X@T&ROF^.KPF]MXY_+_X
M1/=LW*&QG[6,XSUK\:--_P"/^#_?7^=?V:_#W_D0=$_Z\(/_`$6M?J'&&;8O
M!>S^K3Y;WOHO+NO,_/\`AK+</BO:.O'FM:V_F?C8?^#0Z%5)_P"%\MQ_U*7_
M`-UUE>(?^#1758[5GTGXY:?-+CY8[OPL\:D^[I=-_P"@FOW`HKXR/%F:)W]K
M^"_R/J'P[E__`#[_`!?^9_,I^US_`,&]?[0G[*V@7FNP:7IGQ`T"Q4O-<^'9
M7FN(4'5FMG59,`9)*!L`$G%?//[%7[</C[]@CXTV?C'P/J<UK+"ZKJ.F2NQL
M]6A!^:&=!U!&<-U4X(K^NZ>'SACCT/O7\^/_``<U_L":-^SG\?-!^*/A:PBT
MS1OB4\\6J6L"!88=2B"LTB@<#SD;<1CEE<]S7T^1<1O,)_4<?%/F32??RMW/
M`S7(U@H_7,&VN7=?Y'[:_L2_M?>&_P!M[]G/PY\0_"\G^@ZS#BXMF;,NGW*G
M;+!)_M*V?J"I'!%>%_\`!<GQ3JMA^REX>\*:;J-QI$'Q3\;:/X*U.]@;9);V
M-W)(9]K=MRQ[/HY'>OSY_P"#3K]I^YT+XP>/?A%>7#MINO6(\1Z;$S?+%<PE
M(9\#U>)HR?\`KB*_7/\`;K_9&TW]MO\`9PUWP'J-[)I4UZJ76FZE$I:72[Z%
MA)!<*,C.UP,C(R"1D9KY3&8..79I[*?PIIKT?^7Z'T>$Q4L9@/:0^*UOGU^_
M]3\[/VV$\`?LR_MRWGA;5]&^-2?"GP)\*["[M=,^&^H75K#HQ6[G1KJY$,\2
MA"@P9&SEL9SUK!\>>$_&OPG_`&#OA?\`M`>()=8MO'_@KXC6\_@Z^U6]2[UJ
MZ\*W]VL4-A?7"$^=O@ER>3@=,9(KV#P)XU\?_`;XZ:SXE^/'P.^*7C?Q??\`
MA*+P->:KX$T^#7?#OB&SCG>07'E%HY8)9-Y#(XV\G@`XJM^RI^PE\0OV@M5\
M#:!XGT+Q1\/_`-G+X6ZZ_B7P[X;\574-QX@UFX5V>TMYEB!$-G;LQ*QR,[D`
M`\8V^G[:%.$74DK1M=WOS:--15]W^*WL<;IN;ER==E;;5:OT]?O/TYM\F%#G
MC%24R!/*B5?[HQ3Z^,5NA]&%87Q,\.7OB_X>ZYI>G72V-_J-A/;6URREA;R/
M&RJY`Y(!(./:MVH[N[BL+62>>1(885+R2.P544#)))Z`"J3L[H35U8Y#]GSX
M):/^SK\%O#/@G0X$ATWPU81V41"@-*5'S2-ZN[%G8]V8FNSI(W61`RD,K#((
M.012T2DY-RENP225D%%%%(84444`%%%%`!1110!\<_\`!8'PQJ?B?P3X*33=
M.O\`47AOKDNMK;O,4!C4`D*#BOS^U3X<>(H"V_0-<3'7=82C'_CM?N,R!NHS
M044]AQ0!^#&K>'-1LE8S6%["!D'?`ZX_,5SU]$T3?,K+GU%?T"36,-RI$D4<
M@/4,H-9&K_#'PUX@0K?^'M#OE/47%C%+G_OI30!_/W><%JR+P<D^M?O%XI_8
M=^$'C!'%]\.?"99\DM!8);L?^!1[37DWCG_@C7\$O%^]K32M:\/R/_%8ZG*X
M!]=LQD`^E`'Y+>#.J?6O6/!G\-?6?BS_`((7_P!D%Y/"7CEI-IRD&K6>,^WF
M1G_V2O,O%/[`GQ2^#FZ6\\-2ZK8Q];K27%XG'4[%_>@>Y04`4?"<:R*`PROI
M7VU^R+^TY/K8M?"OB6Y:6^(":;?R'F\`'^JE/_/0`<-_&,]P=WQ-X3S%.\3@
MI+$=KHPPR'T(/(/UKU3PG`MU&HWNC+@I)&Y5XF&"&4CD,"`01R"!0!^B(8$D
M#M2UYY^SI\67^)/@YH=0=1KFDE8;U0-HFR"4G4=E<`G`Z,&':O0Z`"D?[A^E
M+2/]P_2FMQ,_E6_X+>_\I6/C3_V&U_\`2>&OVJ_X-G/^45/AK_L-ZI_Z4-7X
MJ_\`!;W_`)2L?&G_`+#:_P#I/#7[5?\`!LY_RBI\-?\`8;U3_P!*&K]*XB_Y
M$E#_`+=_])9\-D?_`"-ZWI+_`-*1^@%%%%?F:/N@HP,YQS2-G:<=>U?*_P"T
M-_P6;_9W_9/^+FI^!?B!\0'T+Q/I*Q/<V?\`8&I77E"1`Z_/!;NARK`\,>M;
M4:%2M+EI1<GOHK_D9U:\*4>:I*R\]#ZIQ17E/[)'[9?P^_;?^']QXL^&NOMX
MC\/VMY)I\ER;"XL]LZ!6*[)XT?A77G&#FO5JFI3G3DX5$TUT94)QFN:+NC\N
M/^#K_P#Y,.\(?]CE!_Z2W%?G)_P;8?\`*67P5_V"]6_](9J_1O\`X.O_`/DP
M[PA_V.4'_I+<5^<G_!MA_P`I9?!7_8+U;_TAFK])RG_DG:OI,^&S3_D<T?\`
MMW\S^F*BBBOS,^["O$O^"DG_`"8!\;O^Q%UC_P!(IJ]MKQ+_`(*2?\F`?&[_
M`+$76/\`TBFKHPG\>'JOS,J_\.7H?R1Z!_R'+/\`Z[Q_^A"O[2$^X/I7\6^@
M?\ARS_Z[Q_\`H0K^TA/N#Z5]UQ[\5'_M[_VT^-X.^"I_V[^HM?E3_P`'9O\`
MR99X`_['%?\`TCN*_5:ORI_X.S?^3+/`'_8XK_Z1W%?,<.?\C*CZ_HSZ+._]
MQJ>C/(_^#090]Q^T$"`0?^$<&#_W%:Q_^#E;_@E4_A+5I?VA?`^FJNG:E*L?
MC&TMX_\`43L<)?X'\+G"2?[11N=S$;/_``:"?\?/[0/U\.?^Y6OV6^(O@72_
MB9X,U+P_K=A;ZIH^LVTEG>VDZ;X[B)U*LK#T()KV,TS*I@<]G7AMI==URK0\
MO+,##%Y/"C/SL^SNS\/?^#:7_@J6/AIXTC^`/CG4MNA:],\OA.[GD^2QO&^9
M[/)Z),<E/23(_C%?M'^T1^T%X:_9G^"7B3QYXJO19:#X9LGO;F0\,^T96-`>
MKNV%4=V8"OYD?^"JO_!/S7_^"8W[6\^EV,E\OAC4)SJOA+5U+*YA#@B/>.DT
M+X4\YX5N`PKIO^"@?_!9OQU^WM^S)\._AUJZ26`\/P>9XFN4D`7Q%?(62&4@
M=%6,!R#QYCL?X5KU,PX>IYA7I8W"/]W/67E_P^WDSBP>=3P=&>&Q7QP^'S_K
M\CSGXL>//B-_P5\_;Z>YM;:2^\3^/]36QTJQWDPZ7:@XCCS_``Q11Y9FQV=N
MIK^B#X<_L7^'?V#/^":/B?X=^'8XY(],\):E)?7VP+)JEV]JYFN'[Y9N@/10
MHZ"OE?\`X-O?^"7S?L[?"$?&;QAI@B\9^.;<+H\,R8DTG3&Y#8ZB2?ACW"!!
MW85^A_[5W_)LGQ$_[%?4_P#TEDKR>(<UC4KPP6&TIP=O5K_+8]+)LME2IRQ5
M;6<_P1_(I\%?^2Q^$_\`L,V?_H]*_LJB_P!4OTK^-3X*?\EC\)?]ABS_`/1Z
M5_97%_JE^E>AQ]_%H^DOT.#A#^%5_P`2_4=7Y'_\'<?_`";1\)?^QHN/_21J
M_7"OR/\`^#N/_DVGX2_]C1<?^DC5\WPS_P`C.CZO\F>YGW^X5/3]4?AIX'\?
MZ]\-M=&I>&];U?P_J2QF,76FWDEK.%.,KOC(;!XR,]J[#_ALGXO*?^2J?$;C
M_J9+W_XY7UM_P;4>'M/\5?\`!3BQM=3L;/4;5O#6I,8;F%98R0(\':P(SS7]
M%D7P3\&F-2?"?ALD@?\`,-A_^)K[W/>(J6!Q7L945/1._KTV9\AE&2U<5AU5
MIU7%7>FO^:/Y'?\`ALKXO9_Y*I\1O_"DO/\`XY1_PV3\7F/'Q3^(WX>)+S_X
MY7]<G_"DO!O_`$*?AK_P60__`!-'_"DO!N,?\(GX:_\`!9#_`/$UXW^NM'_H
M&7WK_(]/_5C$?\_W^/\`F?Q[ZOXWU/XJ^,K2Z\:>*-<U#S'6.;4;V634;B&/
M/)`D?<V.N-PK^B#_`(-[_P!E#X'_``=_9^OO%_PN\8I\1-=\2A+?7-8EMOLL
M]DR886?V=LO"%)W?,3O.&R1C'SC_`,'4_P"R/X%\"_"#X??$?P]X9TG0M?GU
MQ]$O[C3[9+?[?%);O*GFA0`[*83AB,@,1GI7SE_P:Y_&O5O`_P#P4*O/"-O=
MS#1O&_AZZ2YMLYC::WVS12XZ;E`D4'TD->AF=;^TLF>)H7@E=N/>W3]4<N!A
M]0S-8>K[[E:TNJN?T5``#`XI'^X?I38'+Q@GJ1FG/]P_2ORY'WC/X[/VL_\`
MDZGXF?\`8UZI_P"EDM6_"W[97Q@\#^'K/2-%^*GQ'TC2M.B$-K967B6\M[>V
MC'1$C20*JCT``JI^UG_R=1\3/^QKU3_TLEK^DW_@D9\`/`GB7_@FO\%[[4?!
M7A._O;KPM:R37%SI%O++,Q7EF9D))]S7[)FV:T\!@Z52K3YT[*WR/S#+,NJ8
MO$3C3GRVU_'U/YS/^&]/CG_T6;XJ_P#A67__`,=K2\&_MV_'&Y\7:5&_QC^*
M;I)>0J5;Q7?D,"XX.9:_JP_X9C^&W_1/O!/_`(([7_XBA?V9?ANC!E^'_@I6
M4Y!&B6P(/J#LKYN7&.%<6OJR_#_(^@7#-=/6N_Q_S.K\/.9-'@)))**<GOP*
MNTV&%+>,*BA5'0"G5\`W?4^P"O&/^"CW_*//X[_]D]U__P!-UQ7L]>,?\%'O
M^4>?QW_[)[K_`/Z;KBM\+_'AZK\S#$_P9^C_`"/Y&-.N_L%_;S[=WDR+)C.,
MX;.*_:*T_P"#N."TMDC/P5N6*@#/_"2A>@Q_S[FOQ?TJU6^U.VA<D)-*J,1U
M`+8-?O#9?\&F/PDN[1'/Q,^(H+`$_N[/`R,_\\J_6N(9Y6E3_M%-O6UK_/9^
MA^<Y'','&3P+MM>]OEN<'_Q%VP?]$2N?_"F'_P`C4?\`$7=`#_R1*Y_#Q,O_
M`,C5RW[>W_!KNGP5^`&H>*?A!XG\2^,O$&B9N;K1M32$/>6RJ=_V<QHN95X(
M4YW`$#YL`_DOX'MM%M/'NGP^+8M830H[M8]433RD=]%%NP_EB12N\<G##DC'
M&<UY^!RG(<93=3#PO;I>5_NN=N+S+-L-45.M)*_DK??8^P/^"LO_``6C\0?\
M%0='\-Z$WA.U\'>&?#ER]^EJM\;V>[N63RP[N40`*I8!0/XCST`]*_X-;OAS
MJ7B?_@HM>Z_;P2MIGACPS=M>3A3M1IV2*)">@+?.1GJ$;TKZ4_9=_P"#</\`
M9J_:E^&6B^.O"'Q>^(7B7PQJJ"1&MWLHG5@1OBD_<%HW7HRD9!_"OTP_8G_8
M%^&7[`_PVF\-?#G0?[-@O95FO[R>5I[S4I%&`\LC<G&3A1A5R<`9->?F>>X"
MA@)Y?@HM-Z6::M?>]];G=@,HQ=7%QQN*DG;73KVVTL>U"FR]%_WA3@,4V7HO
M^\*_/->I]B]C^1/_`(*+?\G^_&K_`+'C6/\`TMEK^BC_`((`?\HA_@Y_UZZC
M_P"G2\K^=?\`X*+?\G^_&K_L>-8_]+9:_HH_X(`?\HA_@Y_UZZC_`.G2\K]+
MXM_Y%=#UC_Z2?#</?\C&M_V]_P"E(^QJ***_-3[H****`"@G%%8_COQE8?#_
M`,*ZAK6JW<5CIFE6TMW=W$I`2&*-2S,2>P`)HLVTD%TM6?F[_P`'+'[?!_9Z
M_93C^%VAWWE>*?BAN@N2CGS+/2T;]^WJ/-;$0]5,OI7Y\_\`!M]^P@?VI?VS
M$\=ZS9^=X3^%>S4\2)^[N=2))M8\]RC*93_US7UKYD_X*3_MG:A^WI^V%XM^
M(-S).-+NKDV>AVLG'V/3HB5@3'0,5^=O5Y&KZ<_X)L_\%Z[;_@F_^SA:^`M#
M^$%AK-P]Y-J&I:K+KC02ZC<2'`=D$)VA8U1`,GA<]2:_5:>4XG"9/]6PT+U9
M_%Y7_P`EI^)^>3S*A7S+VN(E^[AM\MO\S^CN&+RX=I`QSQ7YS?\`!R1^P9_P
MU#^R"GCS0K%9?%_PK\S408T_>7>FL!]JBXY8IM24#MY;X^\:^8/^(O#6/^B)
M:7_X4<G_`,CU7U/_`(.V]0UFQFMKKX&Z1<6]Q&T4D;^(I"LBL,%2/L_((KYG
M`</YOA<1#$4Z>L7W7W;GO8S.\LQ%&5&=31^3_P`CXP_X(E?M\R?L'_MJZ-?Z
MG>20^"?%X71?$*ECY<44C#RKDCUBD()/78T@[U_499WT=Y#$T;K(LB!U93D,
M",Y![U_&7\0-<TWQ'X[UG4=%TO\`L+2K^]EN++3O.\[[!"SEDA#X&X("%!(!
M.*_HO_X-V?\`@H"O[7/['UOX2UV^\_QM\,$32KSS&S)>66,6MQ[X1?*8]=T6
M3]X5Z_&N6.48YA!=E+]/\G\CS^%\P47+!R?G'^OQ^\_0RBD1@ZY!R#2U^<GV
MC/Y@O^#AG_E+-\2_^N>G?^D,%?LS_P`&Y\:O_P`$B_AAD`XFUCJ/^HM>5^,O
M_!PS_P`I9OB7_P!<]._](8*_9S_@W-_Y1%?#'_KMK'_IVO*_0^(?^1%AO^W?
M_26?$Y1_R.*_S_-'E7_!<3_@AY:?MAZ+J/Q/^&5A::?\4K"+S+NRC`BB\41J
M/NMV6Y`&%?\`C`"L>%(_#7]G;]HGXA_L#_M"6OBCPM=7_AKQ;X=N6@N[.XC:
M,2J&Q):W$1P60D892.V1@@&O[`'0.N#TK\U?^"WG_!$"P_;6T2[^(WPUL;;3
M?BMID&ZX@4B*'Q/$@XC<]!<`9"2'&[A6XP5X.'>(8P7U+':TWHF^GD_+\COS
MG)I2E];P>DUJTNOIYGT=_P`$R?\`@IYX)_X*0?!5=<T64:;XHTQ4CUW099`9
M].E(X9?[\+8.U\<]#@Y%:W_!6?\`Y1K?&W_L4+__`-%&OY@_@#\?_B+^P;^T
M%!XC\,7>H^%?%_ARY:"\M+B-HPX5L26MS"?O*2,,C=",\$`C]W=:_P""FGA3
M_@IM_P`$=OC1JVC-%I?B[2O!M['X@T"1\RV$OD-ET/5X6()5QZ8.#D4\SX>>
M#Q5/$4-:4I+SMJOP[,>79TL70G1JZ5$G\['X>_\`!-?_`)2%?!#_`+'G1_\`
MTMBK^N6W_P!2OTK^1O\`X)K\?\%"O@A_V/.C_P#I;%7]<EO_`*E?I6_'G^\4
MO\+_`#.?@_\`W>?K^@^O./VO_P#DU;XE_P#8IZK_`.DDE>CUYQ^U_P#\FK?$
MO_L4]5_]))*^)P_\2/JCZRI\+/X^=-_X_P"#_?7^=?V:_#W_`)$'0_\`KP@_
M]%K7\96F_P#'_!_OK_.O[-?A[_R(.A_]>$'_`*+6OT#C_P#Y<_\`;W_MI\;P
M=M5]5^IL4445^<GVH5^8'_!U;HUO>_\`!/WP_=2;1/9>,K5HL\DEK:Y4X_"O
MT_K\<_\`@[0^/-C9?"KX:?#6&XCDU34=5F\0W,2L-T4$,;P1DCT9Y7P?6(^A
MKW.&Z<IYG145U/*SR<88&JY=OS/AC_@W3UB?2/\`@K3\.$A)"WD&IP2#LR&P
MG)_50?PK^G,C-?S>_P#!L/\`"^X\<?\`!3BPUM(F:U\':!?W\LFTE5:5!;(#
M]?.8CZ5_2$.17I\:R3QZ\HK\V>?PI&2P3;ZR?Z#!;Q@_<3GVIRQJAR%`/L*6
MBOD#Z5!1110`51\2Z1'X@\/7UA,H:*^@DMW!&?E=2I_0U>H/-`'CG[*OQ8:^
M\.V?A'69676](A,$+RGF^CBRC`'O)&5*L.IVAOXN/8\XKY2_:+\(MX-^*-ZJ
M-)##J+#5]/EB.QH)<@2[&'(99/GS_P!-A[BMCX7_`+;#>'BNG^-HGEB4[8]7
MM8LG'_3:(#@_[29!_NK0!]*T5F^%O%^E^-]*CO\`2+^SU*RE&4GMIEE1_H03
M6E0`4444`%%%%`!1110`4444`%%%%`!1110`4C*'&",BEHH`XOXF_L^>$/BU
M"QUO1;:>Y`PEW$/)N8_<2+AOP)(]C7@/CS]C_6_AB\E[H,LWB32E^9H2@%_`
M/]U0%F&.RA6_V6-?65!&10!\F?!GQDGA'Q?IFLPRAK&5A8WY7H(9&QN8>L<@
M!.?N@R#C)KZS'3TKQ[X_?`R*^M+W7M(@;[9)&W]I6D(P-1C*X9U':91R"/O`
M;3GY2O;_``4\7_\`"=_"[0M4:59Y;FS7SI%Z/*OR2$?\#5J`.JILAQ&QR!@=
M3VIU)(F]&7U&*`]3^5[_`(+FZ=)IG_!5WXS)(.9-6AF7W5[2!P?R-?K=_P`&
MZ/[1/@/X<?\`!,7P[IFO^-?".B:C'K.I.UK?ZO;VTRJ;AB"4=@P!'/2O&O\`
M@X+_`.",'Q!^/?QT7XR?"G2?^$GDU2QBM=>T:W9$O%FA&Q)XE8CS`T852H^8
M&,$`[N/RDU;_`()^?';0;TV]W\'?B7!<)U1_#=X"/_(=?JL8X7-<KI47547%
M1OMNE;9M'YZYXC+\PJ5HTW)2O]S=_,_JJ'[8WPI(_P"2F?#W_P`*&U_^+H_X
M;%^%'_13?A[_`.%#:_\`Q=?RE_\`#"?QL/\`S2/XD?\`A.7?_P`;H_X82^-G
M_1(_B1_X3EW_`/&Z\W_4W!_]!*^Y?YG?_K/B?^@=_C_D?U9M^V-\*?\`HIGP
M]/\`W,-I_P#%U_.%_P`%]?&>D^/O^"HOC_5-#U33]8TVX@T\175C<)<0R8LH
M0<.I*G!R.#7A/_#"?QMZ?\*C^)'_`(3EW_\`&Z[OX+_\$BOVD/CKXEM=.TGX
M1^,;!;EPC7NL6$FFV<`)P6:68*,#T&3Z`UZF49/A,KJ2Q"Q">ENB_4\_,LSQ
M./IJC[%K6_5_H?LE_P`&K%E+;?\`!.C6)9$VQW'C"],9/\0$%L"?SR/PK],3
M7@7_``30_8X@_8-_9`\)_#9+J*_O=)@>?4[N($)=WDSF29U!YV[FVKGG:BU[
M[7YQF^)C7QM6M#9R=C[?+Z+I8:%.6Z2/S!_X.LM*EOOV`?#=R@S#9>,;4R'!
MXW6UP!7YC_\`!O+XVT?X<_\`!4CP=JNO:KINC:9#IFJK)=7UREO"A:RE"@NY
M"@DG`YK]]_\`@IG^Q/!^WW^QUXN^'37<.GZEJ$27>E7<L>Y+:]@;S(2W<*2"
MC$<A7;%?S<_&7_@DA^T;\#?$-U8:O\(_&5XMJQ47NE:?)J-G,,D;EEA#+@^A
MP?4"OM^&,1AZ^5U,#5FHR=]^S/D\^H5J6.AC(0;2M]Z/Z>_^&Q?A1_T4SX>_
M^%#:_P#Q='_#8OPH_P"BF_#W_P`*&U_^+K^4O_AA+XV?]$C^)'_A.7?_`,;H
M_P"&$OC9_P!$C^)'_A.7?_QNL_\`4W!_]!*^Y?YFO^LV)_Z!W^/^1_5I_P`-
MB_"C_HIOP]_\*&U_^+KQS_@H5^U3\-/$?["GQDL;#XA^![V]O/!6K006]OKE
MM+),[6<H554/DL2<`#K7\UW_``PE\;/^B1_$C_PG+O\`^-U);?L$_&^ZE6./
MX0?$J1VX"KX<NR3_`.0ZNEPAA(5(S^LK1WV73YD5.)<3*+C[!J_K_D>=>"=,
M?6/&&D6D7S2W=[#"@'JTB@?SK^SV,YC7Z5_/'_P2-_X(1_%SQW^TMX4\:?$[
MPCJ'@CP/X3U"'5I(-8C\B\U:2%M\<*0'YU4NJEF<#"YQDGC^AU/NCZ5YW&N/
MHXBM3IT9*7*G=KSM_D=G"N#J4:4Y5%;F>E^R%K\J?^#LW_DRSP!_V.*_^D=Q
M7ZK5^97_``=!_"/Q7\9/V1O`^G>$O#>N>)KZV\5K<2V^EV4EW+'']DG7<RQJ
M2!D@9/<UX?#TDLQHN3MK^C/7SF+E@JBCJ['@?_!H)_Q\_M`_7PY_[E:_;&OQ
MW_X-5O@9XV^"-S\=/^$P\(>)?"_]I_V`;3^U=.FL_M/E_P!I[]GF*-VW>F<=
M-P]:_8BMN)YQEF=5Q=UI^2,.'H2A@*<9*SU_-GS9_P`%2/\`@GQH/_!1/]EC
M6/!]\(K7Q#:YOO#NILHW:?>J#MYZ^6XRCCNK9Z@5^,O_``2)_P""(/CGXP?M
MH-_PN'P5KWAWP3\.[H7&I1ZE9200Z[<1R$1VT3,`LL3,A9V3(*#&?G%?T6XY
MI`,5E@<_Q6%P\\-3VE]Z[V_KS-L5E%#$5X5ZBUC]S]2*QL8].MDAA54BC`5%
M4`!0!@``=@*X3]J__DV7XB?]BOJ?_I+)7H-<%^U%97&J?LZ>/+2T@ENKJ[\.
M:C###&I9Y7:VD"JH')).``/6O)HV]I%ONCT9_"S^0_X*?\EC\)?]ABS_`/1Z
M5_97%_JE^E?R3?!_]A[XS6'Q9\+SS_"CXBPPPZO:.\C^'KM511.A))*8``R?
MPK^MB!MT*\$''0]17W/'5:%2I2<))[[/T/D^%*,X4ZJFFO>0^OR/_P"#N/\`
MY-H^$O\`V-%Q_P"DC5^N%?EI_P`'2_P;\6_&?]GKX7V?A'PQK_B>ZLO$<\\\
M6E6$MV\*&V90S",$@9XR:^=X<G&.94G)V5W^3/:SR,I8&HHJ[M^J/SR_X-L/
M%>E^"_\`@II87NL:GI^DV8\-ZDAN+RX2"(,1'@;F(&3Z9K^B2+]HOX>B-1_P
MG?@W.!_S&K;_`.+K^34?L)_&P'_DD7Q(/_<N7?\`\;H_X82^-G_1(_B1_P"$
MY=__`!NON\YR+#YA7]NZZCHELNGS/D,KS?$8.A[!46];]5O\C^LS_AHSX>_]
M#WX-_P#!U;?_`!=))^T;\/E1B/'?@W(&?^0U;?\`Q=?R:?\`#"7QL_Z)'\2/
M_"<N_P#XW1_PPE\;/^B1_$C_`,)R[_\`C=>2N#,-_P!!*^Y?YGH_ZS8G_H'?
MX_Y'ZJ_\'3/[9G@3XE_"3P#\-_#'BG1/$.N6FNR:UJ$6F7D=TMC''`\2"1D)
M"LQE;"YSA2<=,_)O_!M5:2S_`/!5;PQ(BDK;:+J<CG^ZOV<KG\V%>!?#O_@E
MI^T5\4]4BM-'^#/Q!9Y6"^9=:/-9P)G^]+,%11]2*_;#_@A)_P`$8-5_X)_+
MJWCWXA3V,WQ$\16(L(K&U830Z):,ZR.ADZ/,[*FXKPH3`)R37HXVK@LKRF>"
MA54I236EKN_ET./#4\3F&8QQ,H<J5OP/TEMQ^Z&.F.*<_P!P_2DBC\J-5ZX%
M$S;(7/H":_+EN??,_CM_:S_Y.I^)G_8UZI_Z62U_2C_P2*^.?@GP]_P36^"U
ME?\`C#PM8WEMX6M(YH+C58(I8F"\AE9P0?8U_/\`?M0?L2_&/6OVEOB'>6?P
MK^(5U:W?B;4IX98O#]TZ2HUW*592$P5(P01UKA?^&$_C;_T2/XD?^$Y=_P#Q
MNOV#,\OP^8X2E2E64>6SZ/I;NC\UR_%5\#7G-4G*^G5=?0_K,_X:,^'I_P"9
M[\&_^#JV_P#BZ/\`AHOX>_\`0]^#?_!U;?\`Q=?R9G]A/XV$_P#)(_B1_P"$
MY=__`!NC_AA+XV?]$C^)'_A.7?\`\;KY[_4W#?\`02ON7^9['^L^)_Z!W^/^
M1_68?VB_AZ/^9[\&_P#@ZMO_`(NI;+X_>!-3O8;:V\:^$KBXN'$<446L6[O(
MQ.`J@/DDG@`5_)=_PPE\;/\`HD?Q(_\`"<N__C=>F?L7_L6_&#PW^UY\+M0U
M#X6_$"RL;'Q9IEQ<3SZ!=1QPQI=1LSLQ3`4`$DGI6=7@_#0@Y+$IV79?YFE+
MB3$RFHN@]7Y_Y']6(.37C/\`P4>_Y1Y_'?\`[)[K_P#Z;KBO9DY4'CIVKR+_
M`(*!Z+>>)?V#OC5ING6ES?ZAJ/@36[6UMK>(RS7$KV$ZHB*.68L0`!U)KXO"
MM>V@_-'U.)3]E)>3_(_D4\/_`/(=L?\`KX3_`-#%?V?Z/_R#XA_L+_Z"*_D6
MT/\`85^-4.MV3-\)?B,JK.A8GP[=@*-PY/[NOZY]%8MI\>5*G8N0?H*^XXYK
M4YJBH-/XMOD?)\)4IPC4YU:[7ZEB:U6<8.?P[U^,'_!P!_P1)_M@:Q\=?A'H
MS"[3==>+-!M(L_:`,EKZ!!_'CF1`.>7'(;/[1U%=VJWENT;A2K\$$9!'I7Q^
M6YE5P-95J/S7='TV.P-/%TG2J_\`!7H?RM?\$M/^"IGC'_@FA\9%O;$S:SX'
MUB9%U_0)),1W*CCSXL\).@Z-T;[K<8Q_39^S3^TMX/\`VM/@YI/CKP/J]OK.
M@:Q'NCECX>%\#=%(O5)%/#*>0:_&/_@NO_P0IU'P3XQNOBO\$O#]WJ>C:S/G
M7/#6F6QDEL+ASS<6\2<M$Y(W(!E&.1\I^7Y]_P""7GQ6_:>_X)K?&!=4TSX2
M?$[6?!NJR(NO^'WT&\6.]C'_`"UC)CQ'.H)P^.>A!!X^WS7!X3-Z"QV&DHU.
MJ;M?R?GYGRN7XC$Y=7^J5TY0Z-7T_P"`?TN#FFR]%_WA7-_!_P"*EC\:?AWI
M7B73;74[*TU6W6=;?4;1[2[MR>L<L3@,CJ<@@]QW'-=#=2>6JG&?F]<5^<N+
M3Y7NC[6]U='\B_\`P45&?V_OC5_V/&L?^ELM?O;_`,$+OVE_A]X"_P""5'PD
MTG6O'7@W2-3M;:_$UI>ZS;P3P[M2NV&Y&8$9!!Y'0BOQ<_;X_8Q^+_BG]N#X
MO:GIOPN\?WVGZAXQU6XMKBWT&ZEBGC>[D975@A#*00017DO_``PK\;=N/^%1
M_$C_`,)R[_\`C=?L&/P6&S'!4:4ZJC9)]'TMW/S;"XJO@L94JQI.5VUU6[]#
M^K/_`(;%^%'_`$4WX>_^%#:__%T?\-B_"C_HIOP]_P#"AM?_`(NOY2_^&$OC
M9_T2/XD?^$Y=_P#QNC_AA+XV?]$C^)'_`(3EW_\`&Z\+_4W!_P#02ON7^9Z_
M^L^)_P"@=_C_`)']6G_#8OPH_P"BF_#W_P`*&U_^+K7\#_M"^!_B7KO]F^'O
M&7A37K_RS+]FT[58+J8(."VU&)P"1SC'-?R:?\,)?&S_`*)'\2/_``G+O_XW
M7Z`_\&U_[,GQ&^$/_!1B75O%7@/QAX;TQO"=_;B[U+2)[6'S&EMB$WNH&XA3
MQ[5PYCPMAL/AIUH5U)Q5[::_B=.#S_$5J\:4J+2;WU_R/W[+X4FORI_X.=_V
M_C\(/V?=-^#6@7HC\1?$/,VKF)L26FEQMRAYR#-*`ONL<@[U^H_BCQ'#X4\/
MWVHW"3/!86[W$@AC,DC*JDD*B@ECQP`,FOY<_P!N[P/^T)^W'^U7XL^(VJ_"
M3XF1?V]>$:?:OX>N\65FGR6\(^3^&,+GU8L>]</">!IUL7[:LTHPUU[]/\SL
MS_%U*>&]G25Y2TVZ&S_P1J_X)1-_P4Z^*'B2WUG4]6\.^#?"UBLEWJ-C'&TT
MEU*P$4"[P5^Z)')QT0>HK]%Q_P`&E/PJ(_Y*C\0?QBLQ_P"TZ^P_^".G[$47
M["'[$GA;PM<VJP^)]6@76?$4A`WM?3JK-$3Z1+MB'_7//>OJJM\UXIQCQ4_J
MM1J"T6VMNOS,LNX?PT:$?;0O+K<_)/\`XA*/A5_T5'X@_P#?JR_^-T?\0E'P
MJ_Z*C\0?^_5E_P#&Z_6RBO-_UGS7_G\_P_R.W^P\%_S[1^%'_!0G_@V>T3]F
M?]E'Q1X]^'OC#Q7XIUSPM"-0GTV_AM]D]HA_?LOEJ#N1#O\`<(PQG%?"?_!*
M;]N.\_8%_;+\,^,C)+_PCEW(-+\16XSB:PF8!V([M&VV5?=,=Z_JYU?1X-<T
MV>SNHXY[:YC:*:-UW+(C`JRD>A!(K^8/_@I1_P`$E/B-^S;^V1XR\/>"O`?B
M_P`2>#);K^T-#O-+TF>[A%K.2ZPED5ANB.Z,YY.S/>OJ^'<Y>/IU,%F$DW).
MS?GT^6Y\]G.5_5*D,3@XVLUMY?U8_IW\+:Y9^)O#ECJ.GW,-W8W\"7%O/$VY
M)HW&Y64]P0015^OSQ_X-X/C=\0M>_94;X;?$WPKXK\/ZW\.Y%M],N=8TV>U%
M_ISY,2JTBC<T3!D('1/+]Z_0UCM4G&<5\#CL*\-7E1;O9GV&'K>VI1J;7/Y@
MO^#AG_E+-\2_^N>G?^D,%?LY_P`&YO\`RB*^&/\`UVUC_P!.]Y7Y1_\`!=_]
ME#XH?$__`(*@_$/6?#GPZ\;:[I%TE@(;VPT6XN()2ME"K;71"IP01U[5^N'_
M``0#\#:Y\-/^"67PYT3Q'H^I:#K%I+JQGLK^V>WN(=VJ73KN1P&&58$9'0BO
MML_K4Y9+AX1DFUR_^DL^3RBE-9M6FUH[_FC[.ILD8DC93D!ACBG45\`?9GYN
M_P#!;C_@B-IG[;_ARX\?_#RTM],^+&F0$R1KMCA\2QJ,B*4\!9AC"2?\!;C!
M7\%/AG\4_&G[(/Q)\0V\,-WH^J3V%_X9U_2KR%XQ/!-&T,]O-&<$%2=PS]UT
M4CI7]AI&:_.;_@M9_P`$2M(_;E\)7'CKP'!9Z3\6M+A+9$8CA\1QJ/\`4S'^
M&4#A)#[*W!ROVG#G$:HKZIC=8/1/M_P/R/EL[R5U)?6<+I-;^?IY_F?AC_P3
M7_Y2%_!#_L>='_\`2V*OZY+?_4K]*_EJ_8%_8D^,7@+]OKX17>L_"[Q]IMGI
M'C?2Y+RXN-#N4AMDCO(][L^S:%`!);.,"OZE+4[H%/'2M..*L*E>E*#3]WIZ
MD<)TIPH5%-6U_0DKSC]K_P#Y-6^)?_8IZK_Z225Z/7GG[6-C<:M^S/\`$*SL
M[>:[N[SPQJ<$$,2EGE=K60*J@<DDX``]:^,H-*I&_=?F?4U/A9_'KI[!+Z`G
MH'7/L,U_7;X$_:_^%EMX)T>*3XD^`(WCLH597\06H92(UX(W\&OY8O\`AA/X
MV`<?"/XD?^$Y=_\`QND/["?QMS_R2/XD?^$Y=_\`QNOUW/<LPV9\G-64>6_9
M[V\_(_-\IQV(P#FE2<K^JV^1_5H?VQOA2!_R4SX>_P#A0VO_`,76-KW_``4$
M^!_A>"634/C'\++-8@2QF\4V28_.6OY9/^&$OC9_T2/XD?\`A.7?_P`;JWH_
M_!/;X[Z]<>3:?!SXF7$AP-J>&[LG_P!%U\__`*FX+KB?R_S/7?$V*_Y\?G_D
M?O1^UY_P<B?`#X`^&KR+P?K)^)_B949;>TT>-ULM_8R73`($]=F\^@K\"/VP
MOVM_&/[<?[0.L_$+QI<I/J^L2*D-M#E;>P@7B.WA4DD(HZ9)))))))->\_!+
M_@@7^U'\:K^!!\.;CPK9RGYKOQ%<QV*1#/WC'DR_DF:_5+_@FE_P;@^!?V4?
M$FG>,?B5JL'Q%\::>XN+2U%OLTC2Y1R'5&RTSJ<$.^`.R`@&NRC5R?)8.5.?
MM*C7>[]--$<]2GF>:24*L>2'I_3;-?\`X-Q_^"=^H_L?_LS7WC3Q78R6/C+X
MFO%=-;2KMET_3XP?L\3CJ'8O)(P]'0'E37Z/CI]*;!`((E0=%Z4^OSO'8VIB
MZ\L15WE^'9?<?:8/"PPU%48;(****Y3H"BBB@`HHHH`X#]HOX5R?%#P%(MDJ
M#6=+8W5@Q./,<##1$]A(N5SV)5OX:^)/$\HFB9BCHPRK*Z[60CAE([$'(([$
M&OT9<90@9YXXKYC_`&R_V;[EGNO%_AVV:;>-^K64:Y9\#'VB,#JP``=1R0-P
M&<[@#Y&C\:ZQ\.M;;4=`U74-&OLC?-:3-$90.@<`X<>S`BO0_!O_``5:\<^`
MT6'Q!INE>*;=``7_`./.Y(]2R@H3_P!LQ7E'BQ@X9E(96Y!!R#7F?B_HW^?6
M@#[^\#?\%D?A7K;QQ:]#K_ABXQAFGMA<6X^C1DL?Q05[)X(_;>^$GQ%"?V3\
M0?#$[R8`CEO5MY,GMLDVM^E?B5XLZL,G!'/-<@G$AQ@<]J`/Z*]+\1Z?KENL
MME?6EY$_W7@F616^A!P:N!P1WK^>3P[XAU#0V#V5]>6;CHT$[1L/Q4BO0/#?
M[3?Q(\/*HL?'_C6U1?X(];N0O_?._'Z4`?NV&ST!I:_%G1?V[OC#IZ!4^(GB
M5U7IYMQYO_H0-=-8_P#!1?XTQ(`/'>H$#GY[:V<_3F.@#]@**^%?^";7[7/Q
M$^.WQSO=(\5>(Y=7TZ'2);E8FM+>+$BR1*&RB*>`QXS7W50`4444`%%%%`!1
M110`4444`!&:Q_!'@>Q^'^D26&FH8K1[FXNA&3D1M-*TK!?1=SG`[#BM9Y%C
M(R<9Z5E^#_'.D^/]/GN]&O8K^VMKNXL)9(P=J3P2M#-'R!RDB.I]U-.SM<+F
MM0>1112`0J">@)%!4$Y(!-+118$)L&>@H\M?04M%`[B;!Z#\J"@(Q@&EHI6$
M(%`Z`>E+110DEL`$9%-$8`Z#&.G:G44-)[@)L'H*/+7T%+13'<3RU]!1L'H/
MRI:*/4+C3&,?=7\J<!@444K(+A2%<]<9I:*+"L-\I?[J_E3J**86"BBB@`I"
M`>P-+10#0FP>@I0`HP,`444@"D**QY`/X4M%,!-@]!1Y:^@I:*-1W$\M?04;
M!Z#\J6B@5QIC&1@#BE"!6)`'-+10&H4$9%%%`#1&!C@8'M2[!Z"EHI+0!-@S
MT%&P>@I:0L!3N%P*`]A08U/\(_*ESFB@$P`P.*1EW#!`(]Z6B@!OE*.<#-*J
M[1VI:*'KN`4444)@-,8;.0.:41@#&!2T4!=B*@4D@`$T$;AS2T4/4$-$:C^%
M?RI=@'84M%+Y@)L`["C8/04M%/4=Q-@ST%&P9S@?E2T4"8FT>@I#&.>!D^U.
MHH!:"*@3H`/H*6BBBW8`HHHH`*:(5!S@<^U.HH`;Y2[@<#(]J<1GTHHI"2L)
ML'H/RH"@'(`I:*=AA1110`4A7=U`/UI:*6C`;Y8]!^5.`P.***+"L%(5![`T
MM%,;5Q-@]!^5&P>@I:*`$V`=A1M`["EHH`:8PPY`/U&:41JIR`,^N*6BBP:+
M0****`"BBB@`HHHH`****`"D==P-+10!\D?M@?L'3:\;OQ)X%M_])D+37FC+
MA5F/4O!GA6/4IG#=1@DAO@/QS:S6-U/;W$,MO<0.T<L,L;1R1,."K*>5([@\
MBOVSKQ;]J']A[P=^TS9/<7L3:1X@5=L.JV:`2GT65?NR+['!]&%`'XP>+.&-
M<<O^L/UKZ>_:R_8`^(G[.YN;NZTN36]`A)(U73D:2%5]9%QNB_X%QZ$U\PH<
MR-]:`-&Q^Y6I9]*R['[E:EGTH`T[/^M:L'W1]*RK/^M:L'W1]*`/KO\`X(]_
M\G,:C_V`)_\`T=!7Z8U^9W_!'O\`Y.8U'_L`3_\`HZ"OTQH`****`"BBB@`H
MHHH`*;)((U))`P,]:Y3XK?'#PM\$-&;4?%>O:5H-ET22\N%C,S8SM1?O.WLH
M)/I7P7^V+_P6BNIK&YTCX5:9)9EU,9\0:K#AU[9@MFYSZ/+C'_/,UVX/+Z^)
MDHTH_/H9U*L8?$>R?\%5/^"DFD_L8_"NZTC1[N"]^(VMVKKIMHAW_P!FHP*_
M:YL?=4<[%/+L..`Q'JO_``3X^%EY\'?V.OA[HFI^<=731HKS4VE'[Q[RXS<7
M!8]V\V1\GO7XW_L>_`O5OVW/VX=`L-9N+S65N+W^V_$5[=.99);:!U=]['KO
M8I$!V\P8&!7[[0J%B0*`%"@`#H*]+.,)3P5.&$@[R?O2?X+]3GP\W4FZC]%^
MHZBBBO`.PJZOJL.BV$]W<S1P6MK$TLLCG"QJH)+$]@`#7SS_`,/=/V:/^BX?
M#OG_`*C$5>Q_'7_DC7BW_L#7?_HF2OR=_P"#;/\`8G^$G[17[$?B#6_'7P[\
M(^+-6M_%=Q:17>JZ;'<S)$MO;L$#,#A068X]Z]7`X+#U,+4Q.(O:+2LK=;]_
M0\[$XBJJ\*%*UVF];]+=O4_2[X4?M_\`P3^-NKQ:?X6^+7P\US4)SMBL[;7K
M9KF4_P"S%O#G\!7L`D5NC`Y]Z_./_@JI_P`$?OV;-)_8[\?>-;+PGH?PVU[P
MGH\^IZ=K&CG["%N8T+11/&#Y;B1PL>-N[YQM(.*ZW_@WB^/?B_X__P#!.?0;
M[QG>76IWNB:I=Z19WUTQ::\M82OEEFSEBF]H\GDB,9Y%.M@:+PCQ>'D^5.S3
M2ZJZM9ZCIXJI&O\`5ZR5VKIKUMJGJ?>%%&:*\D]!GGWQ1_:>\"?!+QAX=T'Q
M;XMT3P_J_BZ8V^BV=]<K%-JD@9$*0J>7;=)&,#NZ^M>@1MN0$]Z_)_\`X+W?
M\I%?V(O^QJE_]+]+K]7X_N"N_$X-4J%*LG\:;]+.QQX?$NI6J4VOA:7X)_J5
M];U>W\/Z-=W]W-';6EC"]Q-+(<)$B*69B>P`!)^E<K\"OV@_!G[2G@V3Q#X$
M\3Z-XMT2.Y:T:^TRX6>%9E"LT98<;@&4D?[0H_:/X_9X\>_]B[J'_I-)7P3_
M`,&K'_*-+5/^QVU#_P!)K.E2PBEA9XB^L6E;UO\`Y!4Q+CB8T+;IO[K?YGZ5
M4445PG8%9GC'QEI7P_\`#&H:SK>HV>DZ5I=N]W>7=U*L4-M$BEFD=F(`4`$D
MGH*T9I/*B9O[HS7Y@?\`!>+]H?7_`(]^.O`?[(?PTN"WBSXHW4,OB*6(%AIV
MGAR563'16V/(_P#TSB]'KLP&$>)KJE>RZOLENSFQ>)5"DYO5[)=V]D?H3\"_
MVCO`W[2?A>?6_`GBS0?%ND6\YM9+O3+M)XXY0`6C8J>&`*G![$>M=QUK\;/V
M?]";_@A%_P`%4+'X<RZC>'X&_'2T@32[V]DREEJ$86,,[G"AED<JW^Q<1$_=
MK]DHSE!]*TS+!1P\XNG+FA)7B^_?YID8/$NK%J:M*+LU_71]!:***\\[#,\7
M^*K+P1X=OM6U.[@L--TRW>ZN[F8[8[>)%+.['H%"@DGMBO`O^'NO[-&!_P`7
MP^'7/_49BKM_V[?^3,?BS_V)NK?^DDE?GC_P;S_L+_!W]H#_`()V6/B#QK\-
M?!GBC7&UZ_MS?:EID5Q.T:,FU2S`G`R<5ZV$P>&EA)XK$MVBTK*W5>9YV(KU
M57C0I6U3=W?I;MZGZ#?"C]O[X)_&W6(]/\+?%KX>:YJ$[;8K.UUZV:ZD/^S%
MO#G\%KV`2*>C`_C7YQ?\%6/^"/\`^S9I'['/C[QM9>$]#^&NO^$M(GU/3=8T
M<_80+F--T43Q@^6XDD"Q_=W?.-I!Q78_\&\WQX\8_'__`()R^']0\:75WJ=Y
MH^IW>DV5_=,6FO+6$CRV9B<N5+-'N/41C/-*O@:+PKQ>';Y4[--+JKJUGJ%+
M%U%7^KUDKM737K;KJ?=M%%*.M>4CT6>9?'S]KSX;_LO'3C\0O&_AWP<NK>9]
MB.JW2VXNC'C?LW'G;N7./45V7P^^(>B?%3P;IOB#P[JVGZWHNKPBXL[ZRF66
M"ZC/1T8$@@U^37_!SSX)M?B5\7?V8O#EZ\L5GK_B"ZTV=XR`Z1S3V4;%<]P&
M.*ZW_@@U\9]<_9=^./Q#_8Z^(=RRZUX#O;C4?"LDIP+VR<^:Z1YZJ5=;A0.T
MLG]VO?EDZEET<73?O:MKR3M=>AY"S)K&/#S7NZ)/S:O9^NMC]4B0!D\`5P_Q
MT_:/\#?LU>%8=<\>>*]"\)Z1<3BUBN]3NTMXY9B&8(I8\MA6./0$UVTW,3?0
MU^&'_!53Q=J7_!6#]LCQ[X3T"]G_`.%4_LR^%]4U;4KNV;]U=:DD+$KN'RDM
M-&(E_P!F&8CK7'E6`6*J\LW:*U;[=OFV=./Q?U>G>*O)Z)?UT2/VD^"_QP\*
M?M"^"(/$O@KQ#I7B?0+EWBBO].G$\$CHVUE##@D$8-=;7P%_P;0_\HIO"W_8
M9U3_`-*GK[]KGQ^&6'Q$Z"=U%M?<;82LZU"%5JW,D_O0444CL$4D]JXWL=!A
M?$KXD:)\)/!>H>(O$>K6&AZ'I4)GO+^]F6*WM8P0"SLQ``Y[UF?!'X[^$OVB
M?!47B/P5XET;Q5H<TCPK>Z;<+/"9$(#KN4D9!ZBOS:_X+4?%[6/VY_VIOAW^
MQMX"NI(SK-[%K'CF\MSD6-H@\Q(W(XPJ!I2#U;R!WKG?V'-3F_X(R_\`!577
M_P!GK5+BZ'PC^,)74O!-W=R%DM;MN(XBYX+'#6[=RZPGC=7O0R>^%]IS?O&N
M91[Q3M?UZ^AY4\Q<:W+;W$^5O^]V].GJ?KQ13()!*@;UI]>$>JPI&=4ZD#ZF
MEKYV_P""H_[<EE_P3W_9#UWXA3017NJHZ:=HEG(2%O+^8-Y:G!^ZJJ\C#NL;
M8P>:UH49UJD:5-7;T1G5J1IP=26RU/6OC#\??!/P`\+MK/C7Q;X<\)Z8N0+G
M5=0BM$<@9VJ78;F]AD^U?.%U_P`%W/V4[/5S9/\`&'0C*&V[TL[MXL_]=!$5
MQ[YQ7R__`,$Y?^"3$W[;>E:;^T'^U;J&J?$'Q/XQB74]'\.WMPZ:;I=F_P`T
M)>%<##*0RQ#"*K#*L<X_06V_83^#%IX>&DQ?"GX=KIP3RO(_X1RSVE?3/EY_
M6O4J4,!AY>RJ2E.2WY;)7\KW;M\CAIU<55CSP2BGM>[;];6L;GP*_:@^'G[2
MWA]M3\!^-?#/BVTCQYK:7J,5PT!/02*IW(?9@#7>U\6>$O\`@AK\(OA'^U_H
M7Q;^'M[XH^'5QI6Y[G0]`OOL^FZC(2"`ZL&98CSNB4A&XX7!S]I@8KS\7&@I
MKZO)M/NK-/MV9UT)U6K5DD_)A3+AS'"S#.1Z4^FSG$1KFM<W9\[ZG_P5B_9P
MT74KBSO/C5\/;>ZM)6@FB?5X@T;J=K*1V((-0?\`#W;]F?\`Z+A\.O\`P<15
M^='_``0`_9*^&?[2WC7]HN?Q_P"!?"_B^72O%RI9OJUA'=-;J\ER6"EAP"5'
M3TK])Q_P2H_9P_Z(E\-?_!%!_P#$U[^.P&7X6LZ$^=M6VY>U^IY.&Q&*Q%-5
M8**3OWZ.QZ!\`/VI?A_^U%I6HW_P_P#&&@>,++2IA;W<VE72W"6\A&X(Q!X)
M'->@UPGP._9F\`_LTZ=?V7@'PCH'A&SU.59[J#2K)+:.>11M#,%&"0.,UW=>
M)6=/G?LK\O2YZD.;E]^U_(*X'X]_M->!/V8M$LM3\?>+-"\(:=J$_P!FMKC5
M+I;>.>7:6V*6X)V@G'M7?5^4?_!V?_R:+\-/^QN/_I)+75EN$6)Q,*$G92.;
M'8ET*$JR5['ZKVLQG4D]/IBDU"[6QM'F=E1(U+,QZ*`,DT67^K/UJAXX_P"1
M0U/_`*]I/_0#7$E=V.E2O&YR_P`"?VE_`W[2VD7VH>`_%>A^+;'3+HV5W<:9
M<K/';S!0WEL5Z-M*G'O7>U^5G_!J9_R:]\5O^QYD_P#22"OU3KMS/!K"XJ>'
MB[J/7Y)G/@L0Z]"-5JUPKQOXT_M\_![]G+QF/#WCSXE>$?"FM-;I=BRU*_2W
MF,3DA7VMSM)5AGV->R5Y-\7?V%OA!\?O%YU_QO\`#GP?XKUKR$MA>ZGID=Q,
ML2%BJ;F!X!9L#WKFH*CS_O[\OE:_XFM;VG+^ZM?SO;\#B/\`A[K^S/\`]%P^
M'7_@YBH;_@KI^S3T'QP^'0/_`&&(C7YY_P#!R=^QC\*?V=/V4?`6J>!/A]X2
M\)ZA>^-H+*XN=+TR*VDG@:SNW,;,HR5W(IQZ@5^A/@W_`()8_LZ7?A#2I9O@
MM\.))9+2)G=M#A9F)09))'6O9J8/+84(5WS^]?3W>EO\SS:>(Q4J\Z/N^[;O
MU/9_@O\`&_PG^T-X$A\3>"O$&E^)]`N)9(8K_3YA-!(R-M<!AP2#P?>NLKE_
MA!\%O"OP"\%Q^'/!F@:5X:T*&5YH[#3K=;>WC=SER$7@$GD^YKJ*\2?)S/V>
MW2^YZL;V][<*X&U_:<\!7GQXG^&<?B_07\>VT'VJ70!<K]O2'8)-YCZ@;&5L
M^A%=]7Y.^#/^5K_Q/_V*`_\`35;5V8'"*O[2[MRQ<ONM_F<V*Q+I.%E?FDE]
MY^L5%%%<!UA5'7_$=CX9TB>_U"^L]/LK13)/<7,RQ10H.I9F(`'N33/%/B6U
M\'^'[S4[^9+>QT^WDN;B9SA8HT4LS'V`!/X5^-OP;T;QM_P<7_M.>)]=\5:Y
MK/AC]F?P%J/V6PT+3YC;MK4HPR*[=Y"FUY&(.P.JK@G=7?@,#[=2JU)<M.&[
M_))=6SCQ.+]DU"*O*6R_7R1]\?$#_@M?^S!\,]7DL=2^,OA.>YB;8W]G/)J,
M8/\`OVZ2*?P-=I^S[_P4L^!O[4>KQZ?X(^*/A'6=3DQLT_[6+>\E_P!V&7;(
MWX*<4_X2_P#!-;X#_!CPU#IOAWX4>!;2WB0)YD^CPW5Q(!W>68-(Q/<LQ->1
M_M@?\$)O@)^U5:Q7-EX?C^&_BFVF2:#7/"D4=A.N&R0T:CRGR.A*[@>0>QW4
M<L;Y;SCYNS_!?YLSE]=BN:T7Y:K\?^`?9ZR*_P!U@<>AI:Y[X5_#Z/X6?#_2
M/#\6IZQK$>CV<5FM[JMS]IO;H(N`\TI`WN>[8&370UY35FTCO3NKA03@45D>
M/_&VE_#?P1J^OZU>P:=I&B6<M]>W4QQ';PQH7=V/H%4G\*(IMV0_4XWXP_M<
M_#;X#>,=$\/^+_'?A?PUK7B,@:98ZA?)#/>DN$&Q2<D%B!GUKT=)%D^ZRMCT
M.:_!OPY^QWXM_P""\T_Q\_:"OY-1TZ.T0Z1\+[-I/+5GMG\T(W/(V`(Q''FW
M#M_!7Z)_\$-?V]9OVV?V1;>T\0S,OQ#^'A30/$<,_%Q(\8*Q7+@\YD53NX'[
MQ)*]K'Y1&A0]I3E>46E-?RMJ_P!W3U/*PF8NM4Y91M&7POO;?_/T/M.BBBO$
M/5$8X4FN`^(W[3O@/X2>/_#_`(3\2>+]!T3Q+XK81Z/IUY<K%<:D^X)B)#RQ
MW$#CN17?R?ZMOI7Y,_\`!:'_`)3(?L;?]A5/_3A#7?EF#6*KNE)VT;^Y7./'
M8ET*?M$KZI?>TOU/UF7.T9ZXI:**X#L"BB@]*`,KQ?XTTGP'H%SJVLZII^D:
M58(9+J\O+A((+=!U9W<A5`]20*^6O$G_``7-_97\+ZZ^GW/QC\.2SH^PO:0W
M-W!G/_/2*-D/U#8KXM_X.*_'5QXF_;)_9[^%WC'6]0\/_!KQ!<0WNNS1S&&&
M=S>"*7S&Z?NXMI&<[?.)K]&OA7^P'\!?"?PUT_2_#WPP^'CZ%+:H(F71K:Z%
MU&RC#&5U9I-P.=Q8YSG->U]2P]'#TZ^(YFYW:4;))+N[/4\SZU6JU9TZ%ERV
M3O>_?96T.P^`'[4_P[_:B\-'5?A]XU\-^+[*,[9FTR]CF>W/82(#OC.,<,`:
M]"KYP_9V_P""4?P4_95_:*UKXG>!?#,F@^(-:M_LQMX+N1;"S4_?\F`':N\X
M)SD#'RA>:^CP<UYF(5!3_P!G;<?/?\#NHNHX?O59^04445@:A1110`4444`%
M%%%`!1110`DB"5"K#(;@U\^?'_\`X)B_"7]H&2>[NM"_L#6)R6;4-'(MI&8_
MQ.F#&Y]25S[U]"44`?EW\7?^"'OC/PK++/X-\2:3XEM>66"\4V-R!Z9RR,??
M*_05\^^.OV,OBG\*6D_MKP-XA@BC/,\-JUS"?H\>Y?UK]QL9I"H/84`?@%%;
MO;2E)$DCD4X*LI#+]1VK2M^1C@\=J_=3Q)\._#_C)"NKZ'H^JJ1@B[LXY\_]
M]`UQ&L_L7?"C7)-T_P`._".?^F6FQP_^@`4`?#?_``1_?R_VE]2]M`GZ\?\`
M+:"OTN>["XX))K\@?^#C+0T_8A^'?POUGX0W.I_#C5-;U>\L[Z[\/7\]C+=0
MB%&$;%'!*[@#CID"OSA\$?MG_&#7G_TWXK_$RY$@`8/XGO2&^H\VOJ,MX6J8
MS#+$J:2=]->AX]?.(4L0\.XNZ_RN?U-_;5`YX^IJI?\`BJPTNW:6YNK>WC3E
MGEE1%4>N2:_G`\*_%3Q5XDVG4_$_B/4=W!^U:G/-GIUW.?05ZQ\/M%L]4NDD
MN;.VN'SG=+$KM^9%:SX4=/XJGX?\$ZH8Q2U2/VSU_P#:X^&7AF0I>>//"<<H
M./+75(7D_P"^58G/MBLA?VU?!NJ$+HD/B7Q&Y^Z-/T:XV-]))%2/'ONQ7Y^?
M!ZVCM3$L4:1JN``BA0/RKZG^#G+P_2O*Q6`I8?75_,Z8S;5SO/&/[67B6"W9
M])\`M;X!PVNZM%;L#Z[+<3Y^A9<^U>!?%?\`:9^)VOP212^*H-$@;/[K0;%;
M9@/0RRM*YQZH4_"O6_BF!ODX'>OG?XD?ZR7ZFM<OITVU[J^Z_P"9-0^?OB7;
M&]UF?4;N6YO]1G!$EY>7#W-PX]#(Y+$>V<5XEX]E6%9&;(49).*]P^)$@C20
ML54`$DDX`XKWG_@F=_P3Y?XF>)-/^*?C33V30=/F6?P_IURN#J,JD%;R13_R
MR4\QJ?O$;L8"Y^K>,IX6C[6>RV]>QQRIN<M#VO\`X)%?L1R_LR?!>?Q!K]H;
M?QKXU$5S>Q2+\^G6R@F"U]F&YG<?WGQSM!KZ_48`%(D:H3A0/H*=7Y]B<3/$
M576GNST*<%"*B@HHHK%%G)?'7_DC?BW_`+`UU_Z)DK\2O^"$?[`_Q)_:B_9+
MUK7_``A^T=X_^$6G6OB2>S?2-#@\RWGD$$#&<GSD^8A@.G117[=?&6QGU7X5
M^);2VB>>YNM*N(HHT&6D=HG"J/<D@5\.?\&W7[/?CC]FK]B?Q#H7C[PKK7A+
M6+CQ5<7D5GJ=N8)9(6M[=0X![$JPS[5[N6XMT,NK.#7-S1WL^]]&>1B\/[3%
MTFUI:7==NUC/U/\`X-[8OC-JMG)\:/VA_C'\6-/LY1*NG7M]]GMF([8+2%0?
M]D@X)P17WI\&?@]X<^`'POT;P=X2TFTT/P[H$'V:RLK9=L<*9+'W)+$L2<DD
MDDDDUTR\@4M>;B<?B*\5"K*Z6RV2^2T.ZAA*5%MP6KZ]?O"BBC/-<9TVN?D#
M_P`''O@V;XB_MF?L@Z!;ZM?Z#/K>M7EC'J5BVRYL&DN],031'LZ$[@?4"O=T
M_P""'?C!E!_X:_\`VC!_W&#_`/%5S7_!9W]G/Q[\:OVZ_P!DO7/"7A'7?$.C
M^#/$4EWKEY96K2PZ9$;S3G#RL.%&V*0_1#7Z4V[!H5([BOH\1F-2C@L/&A);
M2OHG]I^3MH>)1P,*F)K3JK[2MJU]E=F?FS\8_P#@BMXM\,?"'Q5J<G[6G[0F
MH)IVCW=RUK<:ONBN0D+L8W&[E6Q@CT-)_P`&K9!_X)J:J>@;QOJ''I_HUG7W
M]\>M*N==^!GC2QLX)+F[O-"OH((4&6E=K=U50.Y)('XU\8?\&XOP!\:_LW?L
M":CX>\>^&-9\):X_BZ]O%LM3MS!,T+06JK(%/\)*,`?]DU#Q]2OEU2-:2OS1
MMLN_:P+"PHX^FZ:=N67=]NY]]T445\^>V>=?M3_M'^'_`-E+X!^+/'OB:7R=
M(\+Z?)=R`,`]PX7]W"GJ[N51?=A]:_%K_@D;_P`%!?@KX9_:4^*'[1'Q^\?6
MNG_$[QE?/:Z38-I]U<_V79D`LR-'&R@$".%1G(2$_P!ZOJK_`(+9_!OXQ_M_
M?M(_#;X#^$O"GB:Q^%KZA;ZAXJ\4FV9=.9B2=N_HPAB#,!T:1U'5:^\OA]^Q
MY\,/A]X*TS0K'P#X0%EI%M%9P>;I%O(^R-`B[F*$L<#DDY)YKZ+#U,/A,%:I
M=SJ[V:344]$WKN^G8\6M&M7Q-X62I]T[-OKTV1^8_P#P68_X*%_LG?\`!0?]
MCS4-"T?XFVA\<>&Y?[7\-2G2KU";E1AH-YB`594RO)`#;">E?5O_``0I_P""
M@8_;M_8[T[^V+M9_'?@=$T;7PS?O+DJ,0W1]?-C`)/\`?5Z^HV_9K^'3=?`/
M@K_P1VW_`,17YH^)/V4/B/\`\$W?^"REO\1_A%X&\0>(/@_\5E,?BK3]"LC)
M%I!ED'G-L3A0DNV=,`?*TB#`JJ57"XK"RP<+Q<?>CS-/7K&]EOOZDRA7H8E8
MF;33]V5D_D^NWY'ZR45':OYD"L2<L._6I*^:N>XSR;]NW_DS+XL_]B;JW_I)
M)7Y'_P#!%W_@GY\5/VB_V%;?Q+X-_:9^(GPMTY]7OK>+0M(@+6:2H5S)D3*<
MN2,X7BOU[_;,T"]\6_LI_$K2=+M9[_4]4\+:E:6EK"I:2XEDMG5$4=R20!]:
M^9?^#>[X'>+_`-GO_@GG8^&O'7AG5O"^O1Z]?W+6.I6YAF6-V78^T]C@U]!@
ML7*AEM7D:YN=;V>EGT9Y.)P_M,=#F3MRO9VUT/SP_96_9O?]J/\`;Q\0_`7]
ML?XE_%75/&'AZZ\W0-,N?$#G2?$"J"WREPS`O'^\385+*6&59<']T_A!\+?#
M_P`$_AIH_A3PKI-IH7A[0K<6MC8VR[8X$!/`]22223R223R:^,_^"U7_``3(
MO/VP?AK9?$'X>YTKXS?#@B_T&\M#Y5QJ*1OYGV7>.0X(WQ'L_'`<FO8O^"9W
M[0?Q&^._[.6F2?%GP+XC\"^/]%VV.K0:E9M;1ZBP'RW<.>"KC[RC[K;ATP3>
M:XAXO#PQ-.5DM'#16?=+JG^!.`H_5ZLJ4HW;U4M[KLWW1]'4HZT@H)P*^>/8
M:Z'Y-?\`!QE_R=%^R'_V.3_^E=A71_\`!?;]GS7?A%XD\`_M:_#N`Q^,/A+>
MP)K0C!_TW3B^%9\<E5+M&W_3.9NRUJ?\%UOV;?'_`,>OVB/V8]1\&>$->\36
M/A3Q0UYJ\]A:M*FGPFYLF#R$?=&$<_\``37Z'?$#P+I'Q0^'VK^'=<L8;[1]
M=LI-/O;>505GAE0HZ'V*L17TD<P5"AA*BU24U)>3>J^:/"^J2K5<1%Z7Y;/S
M2T9\1?M\_P#!730?AM_P2ST[XL^"+Q&UWXHZ>+'PK"KAIK>]E0I*Q`YW6V'R
M/[\:CO7%?LM?L&O^P_\`\$1OBG'K<!'CSQQX/U37O$DTHS,DLEG(8[=B>3Y2
M'!S_`!O(>]?._P"PK_P10^(GAO\`X*00>'OB%#K-_P#`OX,:M<:]X7DO07L-
M5EF='@2)3D$[EC>5<8S"0?O5^KO[=/A/4/&?[&GQ1T31;&XU+5=5\*ZE9VEI
M;1EY;B:2VD5$4#J22!5XNIA\(X87"RNI24I/RO[J^2U?F&'C5KJ5>O&S2:2\
M[:OYO;R/E_\`X-H?^44WA;_L,ZI_Z5/7W[7Q/_P0#^"_BW]GW_@G#X>\,>-O
M#NK>%_$%KJNH2RV&H0&&>-'N&9&*GL1R*^V!R*\G.9*6.JRB[KF?YGH9:FL)
M24E9\J_(*\B_;D_:WT/]B#]F;Q3\1]?\N2WT&T+6MLS[6OKI_EA@'N[D#/89
M/:O6KEBENY'4#UK\L/\`@JY\`?BW_P`%,?V\_AO\'X/"?BK1O@;X6NDOO$'B
M*2V>*RU"8C?)L<\,4A'E1G_GI*_;FHRNA3K8A*J[05W+T71>;V*QU6I"B_9*
M\GHO5GSO_P`$5OV^/@1\"?$'Q'^,OQO^)%K'\8OB5J,@FC?3;N8Z?:;][!62
M-E'F28.T$X2*,>HKL/\`@MO^WI^S!^W5^S/:W7@OXFVW_"S_``%?+J_AN1-,
MO(9)VW*);?S&B`7<H5P20-\*=!FOUH\/_LJ_#7P_I5O96_P^\%1VUI$L,*_V
M+;':BC:!RGH!5F[_`&:_AX\)"^`_!BD]"-$M@?\`T"O5><8;ZTL6H2YEM[RM
M9*UK<NUM+'G1RW$>P^KN4;/R=[[WO?>YX7_P1X_;WMO^"@7[&WA[Q)=3Q'Q=
MHB#2/$D(/S+>1*`9<=EE3;(.P+$?PU]6U^3_`,(?V5?B9_P2^_X+'ZS>_#[P
M1XCU_P"`?Q<"-J)TFS::VT"65B07"\*()]Q&!Q!*1VK]7+1B\()).?6O/S;#
MTH5O:8?X))->5]T^UF=^7U*LJ7+67O1T?GY_,DK\N?\`@ZY\%ZIKG[#?@C6;
M2*6XTSP[XRAEU%$!(C62UN(TD;T`?"9]91ZU^HU<;\??@CX>_:0^$VM^!_%F
MG1:KX=\16K6E];2<;D/(93U5U8!E8<@J#6&78Q87%4Z[V3_X?\"L=0]O0E1O
MN9G[)OQ.T3XO?LV>`?$/AR:*XT75_#]E<6CQD;54PJ-F.Q4@J1V*D=J]%!S7
MY.?"_P#9R_:N_P""+FOW^E_##1T_:#^!EQ<R7-MH0NOL^L:+N)9MBD'!SU$8
M=7.6*(2:]6L_^"\>H06?D:A^RO\`M,P:TOR-;0^&?-M]_/'G%E.,XYV5UU\I
MJ3FYX5J<'LTU?YIM-,YZ681C'EQ"<9+R?X-71^AM%?FOX,^*G[:_[>OQZ\,Z
MKI/A]OV:/A7H-V+J[_MG9>:KKB=T>W9<D%3@*5C52=VYB`*_2*SCDC4B1MYP
M!GU]ZX<7A70:C*2;>Z3O;UMI^)V4,0JMVHM+S5K^A-39_P#5&G5'=.(X&8YP
M/2N5&S/P5_X(Y_L(ZW^V/\0/CW<Z3\9?B3\*TT/Q68I8O"U[]G34#)+<$-+R
M,E=I`^IK[H'_``0Y\8?]'@?M&?\`@X/_`,57RA_P37\6_M!?\$U?&_QB1OV6
M_BEXWMO'/B-M0MKBSA-LB1QO,%/*-N#"0$8QTKZO'_!73X^_]&1_&/\`\"!_
M\9K[;-*N.EB92PTH\CM;6'9=]=SY?!0PD:*C74E*[_G[OMH?6/['O[-^H?LL
M?!^'PIJ7CWQ9\1[B&ZFN?[9\13^??.)&R(RV?NKV^M>JC@5\Z_L(_M>^/?VI
MKCQ(OC?X)>,O@_\`V,L!M/[>E\S^T_,,F_R_D7[FQ<_[XKZ*KX_$JHJK]K\7
M6S3_`"T/H\/*G*FG3VZ;_KJ%?E)_P=G1NW[(7PV<(QCC\7'<W9<VDV/Y'\J_
M5NOG7_@J#^P;9?\`!1/]E#6OA_-=0Z;J;.FH:-?R@LEE>Q;MC.!R496=&QSM
M<XR0*Z\HQ$*&,IU:FB3U,,RHRJX6=..[1[YX?U&+5M,BN8'62"X198W!R'5A
MD$>V*J_$&Y2T\$ZK)(P1$M)69CT4!&)-?F%^S/\`\%$/VB?^"?\`X#TWX:_'
M7]GKXE^,X_#,":?8>*/!MM_:OV^WC&V,NH^5F"@#=O4D`;E!R2?M,?\`!1+]
MHG]O_P``:E\-/@7^SS\2_!2>*(WT^_\`%/C2W&E"PMG!678K?(K%21N\QB`3
MM4G!'3_8M95+WCR7^+F5K=_^!N81S*DJ25GS6VL[W'?\&I6X_LK_`!4D"DQ2
M^.I0C_PL19VYX_`C\Z_5.OG'_@ES^P;9?\$[OV3=#\`6]U!J6J>;)J6MZA&I
M5;V]E`WLH/.Q0J(N>2L:DX)Q7T=7/G&*AB,;4K4]F]#?+J$J.&A3GND%%%%>
M:=I^6/\`P=<?\F8_#G_LH%M_Z07M?ISX%_Y$G1_^O*'_`-%K7Y\_\'(_[.WC
MK]I?]EGP)HW@#PGKGB[5+#QK#?7%MIEL9I(8%L[M#(P'10SH,^K5^@_@F-H?
M!VE(Z/&\=I$C*PPRD(`01ZYKU\3*/]G4(WUO/_VT\S#Q?UVK*VEH_J:E%%%>
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M019(3#M\VQF3:V2CC[M>SEU2G4PM3`U)*+DU)-[771]DSR\92J1KPQ,(N2BF
MFEO9_P"1^FE%?G3X?_X+<?$+P'$NG?%+]DSX[Z/KL(VSGPWI8U>UD8=61LQC
M:?JWU-<]\4O^"B/[5/[:^C2^%/@%\`O&GPT&K+Y$_B_QQMTXZ:C<%XHF!PP'
M.X&0CLA.#6<<FQ*?OV2[N2MZ[FKS*CM&[?9)W_(_3>BN`_9@\$>-OAS\$-`T
M;XB>+8O''C&QME34M9BM%M4NY/9%P,`8&[`+8R0"<5W]>9./+)I.YW1;:3:L
M-FD\J(L>U?D;_P`',G[?5OH'ASP_^SUHFM6VE7WC-X;SQ7?L69--T[S,11/L
M!;$CJTC*!G9$."'K]4OBUXOF^'_PSUS6[?2=3UZYTJRDNH=-TZ(RW=^Z*2L,
M2CJ[$`#W-?FC_P`$??V`?&GQ._:)^)_[1'[1O@R6T\8>*]0>RTC0]>L@WV&W
M.TO((I`0%"^7#'W"QOZU[&3>QHREC:^JI[+K*73[M[GF9DZE11PU+1RW?9=?
MOVW.Z_92_P""O_[%_P"R5^SYX7^'GASXG0)I/AFQ2TC<Z-?*]PP&9)G_`'/+
MNY9B?5C7PW>_\%$_A'^R/_P65B^+?PB\6PZ[\+_BJOE>-K&&TGMUL)9I!YLV
MV1%!Q+LN`0#_`,M5XSS^XH_9K^'(''@'P5_X([;_`.(KQ3_@H1_P32\!?M;_
M`+)OBSP5IGA?PQH&NWML;C2-1M-+A@DM;V/YHCN10=I/R,.ZNU=6!S#!1KRY
MXRM4TE>2:UZ_#TW.;%83%NG&SC>%FK)WTZ;]=CZ5T75H-9TJTNK66.XM;J%9
MHIHVW)(C`%6![@@Y!JW7PU_P0B\4_%W1_P!E5?AS\9/!?BGPUKGP\<:?I=]J
MMLR1ZKI_/E!)#PQBP8^/X!'UYK[E%>'BZ'L*\J-[VZK9GKX>M[6FJEK7Z=A)
M/]6WTK\F?^"T/_*9#]C;_L*I_P"G"&OUEEXB;Z&ORN_X+>_!GXIZU^WU^SS\
M2O`'PQ\5_$;3OAVSWVH0Z/;%SN2ZCE$1<`A&8*<$BO2X><5C'S.UXRWTWBUU
M.+.(N6'=NCC_`.E(_5.BOSY'_!77X^`?\F1_&/\`\"!_\9KUO]BW]N_XG?M+
M?%FXT'QC^SK\0/A/ID%D]TNK:U-OMY9%*@0@>6OS$,2.?X37+5RO$4X.<K67
M]Z+_``3-Z>/HU)<L6[^C7YH^JZ**#TKSSL/'/VQOV%?AO^WC\-%\,?$?0(=7
MLX',MG<QL8;S3Y2,&2&5?F0D=1R#W!'%?#TG_!"OXQ?LI64DW[.7[4'C#PU:
MP,7MO#WB",W&GL>H#,A,>,\?\>Y->Z_\%)/B/^UI\$_'/ACQ3\$_#?AOQWX"
MTS+Z[X=48UF]."#AG.#&`05\KYPP&59<BO.(/^"[FO2:*+:?]E']H]?$ZX06
M2>'B]F9?0W!(.,]_*Z5]!@%CH45]7E&47JXMQ=O52V/'Q3PDJC=6+4EL[-7]
M&MSGOV`_^"JWQ=\/_MQK^S/^TMX=TFR\=7*,=)U_2P(X=1(C:10Z+\C+(BL5
MD3;\PVL@.2/TV08S]:_+[]C#]B/XR_M=?\%(K7]JKX\>'+;X=V_AZV%GX6\)
MB82WB*L<B1M,?X0OFR.<X9G;[JJ,']0@,5S9RJ*JQ]DDGRKFY?AYNMOP-\ME
M5<)>TO:^C>[72X4445Y!Z(4444`%%%%`!1110`4444`%%%%`!1110`4444`?
MD5_P=K_\D4^#?_8P7G_I.M?D1\,_]8GX5^N__!VO_P`D4^#?_8P7G_I.M?D1
M\,_];']!7Z[PO_R*J?K+\V?#YA_R,Y?+\CW_`.'_`-U/J*^@/A?UCKY_^'_W
M(_J*]_\`A?UCIXO8]S#_``GTG\)O]9'^%?4GP;^_%]*^6OA-Q(GX5]._##5K
M30M.-[>W-O:6=L@>6::58XXU]2QP`/K7PV;:Z'J4MK'0_%,9DD_&OG#XLZE#
MIBN\K[2[^6B`%GE<G"HJC+,Q/`5023P!7O\`J47B'XX7QA\&Z.]S8R9#:YJ"
MO;:8H_OQ9`DN?;RAL/\`SU%>F?!']CCP[\*]4AUO4))?$OBH*3_:=Y$H%J6Z
MK;1`;(%ZC(RY'#.U<.'Q,*$;SW[=?^`4TWHCYX_94_X)TW'CC6K/Q;\2]-:W
MTJ-Q-8^&YQ\]P0<K+>`'`7H1!G_KIW0?<MK:QV4"QQ($C4851T`]!3HXQ$@4
M9P/6G5P8G%5*\N:;VV78NG34-@HHHKG+"BBB@!KQ*YR1S0D*QDX&,TZBE9`%
M%%%,`HQS110!$;.,L25R3SU-2*H48'`%+12L@$90RD'D&DCA6$848S[TZBF%
M^@4444`,:!&?<1S]:>!@444`%1&SB+9V#-2T4K(!$C$8P!@"EZT44P&/;I(<
MD9/UHCMTB/`Z^]/HH87&O$LB;6&1Z4U+6.,\+C!SU-244N5`%!&X<T44P(S:
M1L02N2.A[TI@4QA,?*!C%/HI60$8M8PP.WD'(.3Q2O`DF=PSGJ*?10DEL`R.
MW2+.T8R,4_I110DEL'F!&1@U&;2,D';TQW]*DHI@`&****5EL`QK9&?<5&0<
MY]Z<B"-<`8%+119`%&***8$9M(R^XKDYSR:!:QA<;1@5)12:0/48MLBG@?J:
M?113L`4DB"1"IY!Z\TM%`$?V6/\`NY_&C[)'_<%244K(!L<*Q?=&*=113`*"
M-P(/0T44`1"SC`X!';@FE^QQD@[>G3FI**5D*RO<14"+@<`4M%%,84444`1M
M:QN22N<^_OFGJH1<#@"EHHL.X4444""F"!!+OQ\WKFGT4K`%%%%,`ILD2RKA
MAD4ZB@35]R,VD9&-O'IDT?94';]34E%*R&&,4444P$=!(I5AD&F+:HA!"X(]
MZDHH`*;)"LJX8<#WQ3J*35]P(X[2.%LJI!^IJ0#`HHI@!&X$'H:8;9&/*YI]
M%*R`C^RQ_P!T4J0)&<@8I]%%EN`4444P&R1+*,,,TW[)'G[N?J:DHH$U?<C%
MM&&#!>0<U)110,****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#\BO
M^#M;_DBOP:_[&"\_])UK\B/AF/WD?X5^NW_!VP<?!3X-^O\`;]Z?_)=:\M_X
M)(?\$&K_`./_`('TOXA_%:ZO=!\*ZBBW.F:';?N[[5(3G;++)_RQB8=`H+L#
MG*\9_4,FS"AA,FA4K.RN_7=GQV*P\ZV9S5-7:M^1\N?#*)]2O;:TMHY+BZG.
M(H(D,DLA]%4`D_@*^RO@/^Q7\7?&D<,EC\//$,$,F")M3B738_KB<J^/HIK]
M8O@;^S!X#_9NTG[!X)\*:)X=MVCV2-:VX$T_3F20_.YXZL37?;!GH.*^<QG%
M,IW5&&GG_P``^CHX-Q7O'PW\'?\`@FUXY8POK_B/1?#D*X#PZ=`^H7!'M+((
MT1O^V<@S7T;X!_8R\%^![FWN[BWN_$NI6I#17FMS?:VB8=&CCXBC.>\:+7JZ
MH%/"J/I2U\[6Q]>K\3MZ:'7&'*,BA$/`Q@#``&,4^BBN0L****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`^'O^"LG[*%M^V5^T?^S'X0U&`7
M.A0>)[_5]7C(^62TMK5971O9V"(?^NE?;=C8Q:=;)#!&L,4:A$11A5`&``/I
M5/4/".G:IXDT_5Y[9)-2TN*6&UG/WH4EV>8!_O>6F?\`=K2'(KIK8F52E3I-
MZ0O^+;,:=",9RJ):O]-`HHHKF-@HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
$B@#_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
